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ABSTRACT

Antimicrobial resistant Neisseria gonorrhoeae (N. gonorrhoeae) has become a major global public
health concern in the 21st century. Surveillance activities are essential in identifying risk factors in
priority populations. The purpose of this study was to identify risk factors associated with and trends
in antimicrobial susceptibility patterns in N. gonorrhoeae strains identified through the Gonococcal
Isolate Surveillance Project (GISP). A study sample of 37,157 men was evaluated to measure
adherence to changes in CDC’s STD treatment guidelines in 2012 and 2015. Data were analyzed to
measure associations between independent and dependent variables by conducting bivariate and
logistic regression analyses. Overall, treatment of gonorrhea was prescribed as recommended. Risk
factors that were statistically significant included both demographic and behavioral characteristics.
Information on treatment regimens following implementation of STD treatment guidelines can be
useful in assessing prescribing practices and adherence to guidelines in treating gonorrhea,
particularly in populations at risk of antimicrobial resistant gonorrhea.
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CHAPTER 1
INTRODUCTION
Introduction and Background
Neisseria gonorrhoeae (N. gonorrhoeae) was the second most commonly reported
communicable disease in the U.S. in 2018 (Bauer et al., 2005; Melendez et al., 2018). Sexually
transmitted infections caused by N. gonorrhoeae can infect the urethral, cervical, rectal, and
pharyngeal sites. Complications can lead to infertility for both men and women and can cause pelvic
inflammatory disease (PID) and ectopic pregnancy in women (Bauer et al., 2005). Vertical
transmission from mother to child during delivery can cause infection in the infant’s eye and
potentially lead to blindness. Gonorrhea infections can also increase the risk of HIV transmission.
The true burden of the disease is thought to be underestimated because it can often times be
asymptomatic and therefore not diagnosed. The Centers for Disease Control and Prevention (CDC)
noted that there’s a high percent of cases of gonorrhea reported per year and estimates have shown
that there could be approximately 820,000 new infections annually (CDC, 2019a).
The risk of acquiring gonorrhea can increase based on the individual’s sexual behavior along
with the prevalence of the disease in the community. The burden of disease at the community level
can be impacted by social determinants of health (i.e., health disparities, access to quality health
care, socioeconomic status). Increased cases of gonorrhea can also be attributed to better screening
practices, especially among men having sex with men (MSM). In 2018, 583,405 cases of gonorrhea
were reported to the CDC, showing a 5% increase since 2017, and an 82.6% increase since the
historic low of 301,174 cases in 2009 (CDC, 2019a). In its 2018 STD Surveillance Report, CDC
indicates that the rates of gonorrhea are highest among men, adolescents and young adults, and Black
men and women (CDC, 2019a). As shown in Figure 1, rates of gonorrhea in men continue to
increase at a higher rate over time, than those in women (CDC, 2019a).
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Figure 1
Rates of Reported Gonorrhea Cases by Sex, United States, 2009-2018 (CDC, 2019a)

Antimicrobial resistant N. gonorrhoeae (AMR-NG) has become a major global public health
concern in the 21st century. As previously noted, gonorrhea cases have increased worldwide in
various settings with an increasing proportion of these cases having resistance to multiple drugs
(Alirol et al., 2017). Factors that can be attributed to this increase are decreased condom use, low
detection rates, increased urbanization and travel, and inadequate or failed treatment (Alirol et al.,
2017).
Gonorrhea has developed resistance to nearly every drug class ever used to treat it, creating
barriers to existing control and prevention methods. Some of the challenges in controlling AMRgonorrhea are the rapid change in antimicrobial susceptibility patterns, frequency of asymptomatic
infections, variety of AMR mechanisms, and a reduction in the use of condoms (Alirol et al., 2017).
The spread of AMR-NG has also outpaced the development of new drugs, further supporting the
notion that untreatable gonorrhea is becoming more of a reality. The World Health Organization
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(WHO) and CDC recommended dual-therapy with ceftriaxone and azithromycin as the first line of
treatment in 2015. It is pertinent that we assess the risk factors associated with AMR-NG in order to
prevent transmission and preserve stewardship of our drugs.
Historically, gonorrhea has been effectively treated using a single antibiotic dose; however,
with the emergence of drug resistance to most classes of drugs, recommendations changed in 2015 to
include dual-therapy. CDC (2019a) has reported that each year, 30% of new gonorrhea cases have a
resistance to at least one drug. Penicillin was the recommended form of treatment from the 1940s
through 1987, following the discovery of penicillinase-producing gonorrhea (Bauer et al., 2005). In
the 1970s and 1980s, resistance to tetracyclines (TetM) developed in gonorrhea strain, and in 1985,
TetM was removed as a recommended treatment after the development of plasmid-mediated
resistance to TetM (see Figure 2; CDC, 2016).
Figure 2
Neisseria Gonorrhoeae – Prevalence of Tetm, Penicillin, or Fluoroquinolone Resistance or Elevated
Cefixime, Ceftriaxone, or Azithromycin Minimum Inhibitory Concentrations (MICs), by Year, from
2000-2018 (CDC, 2019a)

Sporadic cases of fluoroquinolone-resistant N. gonorrhoeae were reported in the U.S. prior
to 2000, but higher rates have been identified in other countries, including southeast Asia and the
Pacific Islands. As fluroquinolone resistance spread from specific populations on the West Coast to
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the general population in the US, CDC stopped recommending ciprofloxacin as a recommended
treatment regimen in 2007. Despite no longer being recommended for use, the prevalence of
resistance to ciprofloxacin has continued to increase in the US and is currently at the highest levels in
US history (CDC, 2019a). With the decrease in susceptibility to penicillin and other antibiotics, there
was growing concern that gonorrhea will develop resistance to commonly prescribed antibiotics such
as quinolones and cephalosporins (Ali et al., 2016). The need to monitor resistance trends has led to
the development of many national and international interventions and surveillance programs.
The transmission of gonorrhea can be prevented through effective treatment, however, its
ability to acquire antimicrobial resistance can impact treatment guidelines and complicate control
(CDC, 2019b). In 2010, due to concerns of emerging resistance to gonorrhea, CDC recommended
dual therapy for gonococcal infections with a cephalosporin (ceftriaxone 250 mg intramuscular (IM)
or cefixime 400 mg orally) and either azithromycin or doxycycline (Workowski et al., 2010). By
2011, an increase in the cefixime MICs required to prevent the growth of gonorrhea influenced the
decision to no longer recommend cefixime for gonococcal therapy in 2012 (CDC, 2012). The 2015
CDC treatment recommendation removed doxycycline as an option for dual therapy for
uncomplicated gonococcal infections and the recommended therapy was a single 250 mg IM dose of
ceftriaxone and a single 1g oral dose of azithromycin (Workowski et al., 2015).
Concerns of antimicrobial stewardship have increased since the publication of the 2015
guidelines. This concern, along with the increase in incident of azithromycin resistance and potential
impact of combination therapy on commensal organisms and concurrent pathogens, warranted the
reevaluation of the 2015 guidelines (CDC, 2019b). In 2018, subject matter experts and CDC staff
members met to determine the questions necessary for updating the 2015 STD Treatment Guidelines
(see Figure 3; Workowski et al., 2015). A thorough literature review was conducted to assess titles
and abstracts related to clinically relevant articles. Antimicrobial susceptibility data from the
Gonococcal Isolate Surveillance Project (GISP) was also reviewed from the time period of January
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2013 to May 2019 (St. Cyr et al., 2020). In a 2019 meeting, subject matter experts met to further
discuss their individual opinions and review the data and the articles from literature search to address
the essential questions. The new and current STD Treatment Guidelines were released in 2020 and
CDC recommends a single 500 mg intramuscular dose of ceftriaxone for uncomplicated gonorrhea
(St. Cyr et al., 2020).
Figure 3
Percentage of Neisseria Gonorrhoeae Isolates with Elevated Minimum Inhibitory Concentrations
(MICs)* to Ceftriaxone, Cefixime, And Azithromycin — Gonococcal Isolate Surveillance Project,
United States, 2009–2018 (CDC, 2019a)

As resistance trends continue to emerge, continued surveillance of AMR-NG is essential in
monitoring decreased susceptibility and increased resistance to ceftriaxone and azithromycin. In
1986, CDC established the GISP to serve as the national surveillance system for monitoring
resistance in strains of gonorrhea in the U.S. The primary objectives of GISP are to:
1) Monitor N. gonorrhoeae antimicrobial susceptible trends;
2) Characterize male patients with genital gonorrhea attending STD clinics, particularly those
infected with gonorrhea that are not susceptible to recommended antimicrobials; and
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3) Phenotypically characterize isolates to describe the diversity of gonorrhea AMR (CDC,
2019c).
There are GISP sentinel sites in approximately 25-30 STD clinics in select U.S. cities that
collect specimens each month for culture and bacterial isolation for susceptibility testing (see Figure
4). Sentinel sites receiving funding from GISP monitor gonococcal resistance by collecting at least
25 urethral specimens each month from symptomatic male clinic attendees. Clinical and
demographic data along with isolate antimicrobial resistance data are collected for each patient.
Antimicrobial susceptibility testing is conducted for penicillin G, TetM, gentamicin, cefixime,
ceftriaxone, ciprofloxacin, and azithromycin. The data generated through GISP are essential
resources in identifying risk factors and trends of AMR-NG in an effort to prevent and control
transmission of resistant infections.
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Figure 4
Location of Participating Sentinel Sites and Regional Laboratories for the GISP, United States, 2018
(CDC, 2019c)

Purpose Statement
The purpose of this study is to identify risk factors that are associated with and trends in
antimicrobial susceptibility patterns that exist in strains of N. gonorrhoeae identified through GISP
participants. The empirical evidence will help to monitor the emergence of AMR-NG, inform polices
around the management of N. gonorrhoeae including treatment guidelines, and targeted interventions
for populations with the highest risks of AMR-NG infection.

Significance of the Problem
The risk factors associated with gonococcal infection may not have the same risk factors
associated with developing AMR-NG; therefore, we must characterize factors associated with AMRNG to assist with addressing the growing threat to public health and informing policies around the
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use of antimicrobials. Understanding these risk factors also helps target interventions to populations
with a higher risk of AMR-NG infection (Trecker et al., 2014). Previous studies have shown
antimicrobial resistance to be associated with behavioral and clinical factors such as poor prescribing
practices and antimicrobial management, infection with previous STIs, site of infection, sexual
orientation (MSM vs. MSW), risky sexual behavior, and substance use and abuse. Some of the
demographic characteristics identified in previous studies differences in resistance by gender, age
category, urban or rural residency, and race or ethnicity. Rates of AMR-NG have been shown to be
highest among men and young adults (Cole et al., 2014). The ability to link epidemiological and
behavioral data to the AMR profiles of gonococcal isolates will allow us to identify those at higher
risk for AMR-NG infections. The clinical and demographic data collected through GISP will be
essential in helping us to identify risk factors which could subsequently be used to implement
behavioral risk reduction and other interventions as prevention efforts.
As N. gonorrhoeae continues to retain resistance to previously recommended antimicrobials
while also becoming less susceptible to currently recommended treatment options, it is critical to
understand the risk factors associated with AMR-NG in the U.S. The 2015 CDC-recommended
treatment therapy for gonorrhea was ceftriaxone (a cephalosporin antimicrobial) combined with
azithromycin. There is a major concern for the spread of the extended-spectrum cephalosporin
(ESC)-resistant N. gonorrhoeae, given that the emergence of a strain with this resistance pattern will
severely limit treatment options for gonorrhea (Unemo et al., 2019). ESCs, , specifically cefixime
and ceftriaxone, are the last remaining and only first-line options of antimicrobial monotherapy that
are available for the treatment of gonorrhea in most global settings (Unemo & Nicholas, 2012).
Since its inception in 1986, GISP continues to serve as the primary and oldest continuously
function surveillance system for monitoring AMR-NG in the U.S. (Unemo et al., 2019). Treatment
recommendations and guidelines generated by CDC utilize data provided by GISP to make these
pertinent decisions. GISP findings have directly contributed to CDC STD Treatment Guidelines in
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1993, 1998, 2002, 2006, 2010, and 2015, along with updates to recommendations in 2000, 2004,
2007, and 2012 (CDC, 2019c). As it relates to understanding resistance trends and identifying risk
factors associated with AMR-NG, GISP is the best data source for evaluating these outcomes in the
U.S. GISP can detect changes in susceptibility patterns and to identify resistance strains sooner and
can maximize the accuracy of surveillance.
The public health threat of untreatable gonorrhea further indicates how essential it is to
understand resistance trends and risk factors associated with AMR-NG in order to prevent the
emergence of new resistance strains and the further spread of others. This study aims to provide
additional context to the AMR-NG literature, heighten awareness regarding the importance of
enhanced surveillance of AMR-NG, and provide information to target preventive measures to those
individuals at the highest risk.

Research Question and Hypotheses
The research questions and hypotheses that guide this study are:
•

Question 1: What trends in antimicrobial susceptibility patterns exist in strains of N.
gonorrhoeae among men who received the recommended treatment per STD Treatment
Guidelines versus those who received alternative regimens?
o

Hypothesis 1A: Men who received alternative treatment regimens for Neisseria
gonorrhoeae are more likely to have resistance to multiple drugs than those treated
per treatment guidelines.

•

Question 2: What risk factors are associated with having received treatment per STD
Treatment Guidelines versus not?
o

Hypothesis 1B: Black men are more likely to have not received the recommended
treatment compared to men in other race categories.
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o

Hypothesis 2B: Men between the ages of 15-24 are more likely to receive alternative
regimens than other age categories.

o

Hypothesis 3B: Men who have sex with women only (MSW) are more likely to have
received an alternate method of treatment compared to men who have sex.

o

Hypothesis 4B: Men with previous confirmed episodes of gonorrhea in the past year
are more likely to have received the recommended treatment regimen than men with
no prior episodes.

o

Hypothesis 5B: Men who have a history in the previous 12 months of risky sexual
behavior or drug use are less likely to have received the recommended treatment.

o

Hypothesis 6B: Men in the South are more than likely to be treated with alternative
regimens than those in other regions.

In a similar study in Italy, a time trend analysis between 2009-2016 was conducted following
the introduction of combined antimicrobial therapy for gonorrhea to assess susceptibility trends with
the change in prescribing practice in 2012 (Stefanelli et al., 2017). The findings in this study along
with other literature helped to shape the hypotheses constructed to address our research questions.
The literature reports that there are higher rates of antimicrobial resistance gonorrhea for Blacks due
to limited access to treatment and a prior history of gonorrhea (Barrow et al., 2018). Stefanelli and
colleagues (2017) found that MSW were more likely to have received therapy discordant with the
recommended guidelines in comparison to MSM. In the present study, we assume similar findings
among sexual orientation. Individuals that were older than 25 years of age were significantly more
likely to receive alternative treatment regimen than those younger than 25 years old (Stefanelli et al.,
2017). Similar to previous findings, young adults between the ages of 20-24 and 24-29 years old
make up 25% and 24% (for a total of 50%) of gonorrhea cases in this study, respectively. Men who
had a previous history of gonorrhea were 3.6 times more likely than men with no previous diagnosis
to have received a treatment regimen discordant with guidelines (Stefanelli et al., 2017).
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Delimitations
The data used in this research study is secondary data generated through GISP, which is
limited to approximately 25-30 STD clinics in 15 states across the United States. Not all sentinel
sites were reporting for all years during the study period, so there may be variability in
representation. The study population is a subset of the GISP data restricted to include only individual
cases having received two forms of antimicrobial treatment. It is assumed that resource information
from GISP is up to date and accurate in the current dataset.

Definition of Terms and Abbreviations
1. AMR-NG: Antimicrobial resistance Neisseria gonorrhoeae (Alirol et al., 2017).
2. Antibiotic stewardship: Interventions designed to improve the appropriate use of antimicrobials
by promoting the best agent selection, dosing, duration and route of administration (Alirol et al.,
2017).
3. Antimicrobial Resistance: The ability of a microorganism (e.g., bacteria, virus, fungi, etc.) to
resist the effects of medications used to cure the infection (Unemo et al., 2016).
4. ARLN: Antibiotic Resistance Laboratory Network (CDC, 2019c).
5. AST: Antimicrobial susceptibility testing is a procedure used to determine which antimicrobials
a specific organism or group of organisms are susceptible to (CDC, 2016).
6. CARB: National Strategy to Combat Antibiotic-Resistant Bacteria (CDC, 2016).
7. Dual Therapy (also, Combination Therapy): Refers to using multiple therapies to treat a disease
or condition (CDC, 2019c).
8. EGASP: Enhanced Gonococcal Antimicrobial Surveillance Program (Weston et al. 2017a).
9. eGISP: enhanced Gonococcal Isolate Surveillance Project (CDC, 2019b).
10. GASP: Gonococcal Antimicrobial Surveillance Program (Weston et al., 2017a).
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11. GISP: Gonococcal Isolate Surveillance Program (CDC, 2019c).
12. Isolate: A pure laboratory culture containing a single species of organism typically used to
identify microorganisms. Isolates for N. gonorrhoeae are typically retrieved from sites of
exposure (e.g. urethra, endocervix, throat, rectum) (CDC, 2016).
13. MIC: Minimum inhibitory concentrations are the lowest concentration of an antimicrobial that
will inhibit the visible growth of a microorganism (CDC, 2019c).
14. MSM: Gay, bisexual, and other men who have sex with men (CDC, 2019c).
15. MSW: Men who have sex with women only (CDC, 2019c).
16. NAAT: Nucleic Acid Amplification Test (CDC, 2016).
17. PID: Pelvic inflammatory disease (Alirol et al., 2017).
18. Reduced Susceptibility: Occurs when a microorganism has an elevated MIC and becomes less
vulnerable to a given antimicrobial. Can be a sign of potential antimicrobial resistance and
treatment failure (Unemo et al., 2016).
19. GISP Sentinel Site: STD clinics in states and/or jurisdictions receiving CDC funding to collect
gonococcal isolates (CDC, 2016).
20. TetM: Tetracycline (Bauer et al., 2005).

Chapter Summary
Gonorrhea was the second most commonly reported notifiable disease in the United States in
2018 and AMR-NG has become a major global public health concern in the 21st century. Gonorrhea
has developed resistance to nearly every drug class ever used to treat it, thereby, creating barriers in
the control and prevention methods currently in place. Understanding of risk factors and early
detection of AMR-NG are essential in preventing the further spread of these increasingly difficult to
treat strains of gonorrhea. In 1986, the GISP was established by the CDC) to monitor susceptibility
trends in N. gonorrhoeae in men and to support the rationale for determining the selection of
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treatment therapy for gonococcal infections. In 2017, GISP was expanded to the eGISP to evaluate
differences in antimicrobial susceptibility between men and women and to conduct surveillance on
urethral and non-urethral isolates.
WHO and the CDC currently recommend dual therapy with ceftriaxone and azithromycin as
the first line of treatment. A high level of resistance to this regimen has been reported in 2016
indicating a failure of clinical treatment. The emergence of resistant strains of gonorrhea and other
bacterial infections to current antimicrobials poses a major threat to public health. The risk factors
that we see for higher risk of gonorrhea are not necessarily the same risk factors associated with
AMR gonorrhea. Therefore, it is pertinent that we assess the clinical and behavioral risk factors
associated with antimicrobial resistance gonorrhea in order to prevent transmission and preserve
stewardship of our drugs. The current state of the literature on the topic is addressed in the next
chapter.
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CHAPTER 2
REVIEW OF LITERATURE
Overview
This chapter discusses the literature on AMR-NG and its role on human health, threats to the
stewardship of antimicrobials, impacts of policy on surveillance and treatment, and the
epidemiological and clinical risk factors associated with transmission. In an effort to assess the
effects of AMR-NG on human health, the history and effects of untreated gonorrhea will be
reviewed in the existing literature. The epidemiology of AMR-NG and the timeline of reduced
susceptibility and resistance to antimicrobials will contribute to our understanding of resistance
trends in order to identify populations that are most at risk. Surveillance is also a key component in
monitoring current and evolving resistance trends, so it is critical to evaluate surveillance methods to
control the progression of resistant strands. Furthermore, the upward trend in resistance poses a
major threat to antimicrobial stewardship. A lack of funding for research and an absence of change in
policy further hinders efforts to effectively treat and contain transmission. This review of literature
provides a summation of current information to help identify gaps in research and improve future
methodology.

History of Gonorrhea and Difficulties in Treatment
N. gonorrhoeae is the second most reported sexually transmitted infection in the United
States and has an estimated incidence of 78 million cases worldwide (Melendez et al., 2018).
Although gonorrhea has been around since biblical times, the etiologic relationship of the STI was
not established with humans until 1985. The disease quickly became a major public health concern
on a global scale and will continue to rise over time. From 1975 to 1997, the rates of gonorrhea in
the U.S. had shown a steady decline following the implementation of a national gonorrhea control
program (Vicentini et al., 2019). Rates remained steady following this period then began to increase
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in the late 1990s and early 2000s, as shown in Figure 5. There were a total of 583,405 cases of
gonorrhea reported in the U.S. in 2018 which is an increase of 5% from 2017, 63% increase since
2014, and an 82.6% increase since 2009 (see Figure 5; CDC, 2019a). This increase in incidence
since 1997 can be attributed to the growing numbers of treatment failure as a result of untreatable
multidrug-resistant gonorrhea strains.
Figure 5
Gonorrhea – Rates of Reported Cases by Year, United States, 1941-2018 (CDC, 2019a)

When left untreated, gonorrhea can create more serious and complex outcomes such as PID,
ectopic pregnancy, sterility, septic arthritis, and occasionally death (Vicentini et al., 2019).
Gonorrhea can also be debilitating and was responsible for 445,000 YLD in 2015 (Vicentini et al.,
2019). The ability of N. gonorrhoeae to alter its DNA in hostile environments and its capacity to
naturally transform during a lifecycle makes it more susceptible to mutations and essentially difficult
to treat (Unemo et al., 2019). Other factors that impact the morbidity of gonorrhea and essentially the
ability to treat those most at risk are socioeconomic status, access to quality health care, and
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discrimination. Studying the evolution and history of the bacterial pathogenesis and resistance
patterns of gonorrhea can provide us with a better understanding of its ability to cause repeat
infections and the trend in developing resistance to all antimicrobials used for clinical treatment.

Effects of Untreated Gonorrhea
Gonorrhea is a debilitating disease that can lead to further complications and possibly
mortality if left untreated. In 2015, gonorrhea was responsible for an estimated 445,000 YLD (Alirol
et al., 2017). It is not uncommon for both men and women with urogenital gonorrhea to lack
symptoms, with 40% of men and more than half of women being asymptomatic (Alirol et al., 2017).
An untreated urethral infection in men can lead to epididymitis, reduced fertility, and urethral
stricture (Alirol et al., 2017). Symptoms in women can include an abnormal discharge, pain or
discomfort in urination, lower abdominal discomfort, and dyspareunia (Alirol et al., 2017). However,
symptoms are oftentimes not discernible when present in women and can lead to unrecognized and
untreated infections, which in turn, lead to complications. PID develops in 10-20% of female cases
and places the women at a higher risk for infertility (Alirol et al., 2017). Untreated gonorrhea can
also cause complications during pregnancy such as chorioamnionitis, premature rupture of
membranes, ectopic pregnancies, preterm birth, and other difficulties (Alirol et al., 2017). Perinatal
transmission can also occur if a mother is infected at birth. The infants exposed during delivery can
contract neonatal conjunctivitis which may lead to scarring and blindness if left untreated.

Epidemiology of AMR-NG
Disease burden and increased incidence. Gonorrhea is a growing concern worldwide as
the disease burden continues to rise across countries with an increasing proportion of cases having
multidrug-resistance (Alirol et al., 2017). A majority of the drug classes that are typically used to
treat gonorrhea have lost their efficacy and now have reduced susceptibility or have acquired
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resistance to the bacteria. The concern of potentially reaching a place of untreatable gonorrhea has
sparked fears internationally. These resistance strands are not limited to borders and therefore it is
essential that international efforts are in alignment. Collaborations across political will, advocacy,
research, and funding are all key components in these efforts (Unemo et al., 2019). As a result, in
2012, the WHO, CDC, and European Centre for Disease Control and Prevention (ECDC) published
a global action plan as well as regional response plans in an effort to contain and reduce the spread of
resistant strands of gonorrhea to multiple drugs (Unemo et al., 2019).
Although there are efforts in place to improve international awareness and collaborations,
the rate of new gonorrhea infections continues to escalate worldwide. The United States reported a
rise of 11% in gonorrhea cases between 2014 and 2015 (Alirol et al., 2017). Other countries that also
saw an increase in gonorrhea cases were France in 2013 and 2015, where the number of cases among
MSM doubled, and Australian states between 2010 and 2014 with a rise in trends from 29% to 146%
(Alirol et al., 2017). The African region has the highest rates of gonococcal infections with 50 and
100 new cases every year among women and men, respectively (Alirol et al., 2017).
The WHO plans outline improvements that are significant in reducing the global burden of
AMR-NG. These plans make note of necessary improvements in prevention and control, treatment
and surveillance, contact tracing, and diagnosis of gonorrhea (Unemo et al., 2019). There’s also a
need to refocus efforts on reducing the rate of gonorrhea among higher risk populations such as
commercial sex workers and MSM. This can be done by promoting effective preventive measures
such as using condoms during oral sex. Given that the actual global burden of disease is unknown, it
is also critical that global efforts work to improve the quality-assured surveillance of AMR-NG and
that failures in gonorrhea treatment, when using the recommended treatment regime, are verified
both domestically and internationally (Unemo et al., 2019).
Timeline of reduced susceptibility and resistance. Historically, the treatment guidelines
for gonorrhea have changed over time to adapt to the influx of resistance to previously susceptible
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antimicrobials. A historical perspective designed to summarize the timeline of introduction of the
various antimicrobials for treatment of gonorrhea will be displayed in this section. Reduced
susceptibility in gonorrhea date back to over 70-80 years ago as a result of N. gonorrhoeae’s
capacity to develop (Unemo et al., 2016). Historically, there has been a wide range of antimicrobials
used to treat gonorrhea ranging from sulphonamide, penicillin, and tetracycline to fluoroquinolones,
macrolide, and cephalosporine.
The first antimicrobial used to treat gonorrhea in the mid-1930’s was sulphonamide. By the
late-1940’s, sulphonamide developed resistance to gonorrhea in over 90% of gonorrhea isolates
(Unemo et al., 2016). This then led to the U.S. removing sulphonamide as a recommended treatment
due to the high prevalence of resistant strains. Following the cessation of sulphonamide to treat
gonorrhea, penicillin was discovered in 1928 and quickly became the first-line treatment
recommended for gonorrhea in 1943 (Unemo et al., 2016).
Over the next decades, the MICs for penicillin increased in gonococcal isolates, thereby,
leading to the emergence of chromosomally-mediated clinical resistance to gonorrhea in various
countries (Unemo et al., 2016). By 1976, these resistance strains originating in Southeast Asia and
Sub-Saharan West Africa will eventually make its way to the U.S. and United Kingdom. As of
today, chromosomally- and plasmid-mediated resistance to penicillin are common gonococcal strains
worldwide (Unemo et al., 2016).
Early in the treatment of gonorrhea, patients with an allergy to penicillin were treated with
tetracycline instead; therefore, after the removal of penicillin as the recommended treatment for
gonorrhea, tetracycline will move to serve as the first-line treatment method. However, tetracycline
resistance gonococcal strains will eventually emerge as a result of accumulation of chromosomal
resistance determinants (Unemo et al., 2016). The MICs for tetracycline gradually increased, and in
the mid-1980s, plasmid-mediated resistance to tetracyclines would result in its exclusion for
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treatment guidelines in the U.S. and other countries alike (Unemo et al., 2016). These plasmidmediated resistance gonococcal strands are now present worldwide.
Spectinomycin is an aminocyclitol antimicrobial synthesized in the early l960s and also used
to treat gonorrhea following the emergence of plasmid-mediated resistance in penicillin (Unemo et
al., 2016). The first case of resistant gonorrhea to spectinomycin was reported in the Netherlands in
1967 (Unemo et al., 2016). Korea used spectinomycin to treat gonorrhea in U.S. military personnel
in 1981, and by 1985 8.2% of the gonorrhea cases were resistant to the drug (Unemo et al., 2016).
Spectinomycin is no longer available for use in the U.S.
Beginning in the mid to late 1980s, fluoroquinolone became the first-line of therapy
recommended for the treatment of gonorrhea worldwide (Unemo et al., 2016). Ciprofloxacin and
ofloxacin were the primarily used in this drug category. The Asian Western Pacific Region was the
first region in which resistance strains of ciprofloxacin emerged leading to the spread of the resistant
gonococcal strains internationally. This then led to the dismissal of ciprofloxacin as a first-line
treatment in the mid-to-late 1990s (Unemo et al., 2016). In 2000, ciprofloxacin resistance strains first
emerged in the U.S. in Hawaii, so it easily made its way to the West Coast and eventually throughout
the rest of the country. By 2007, CDC changed recommendations to exclude all fluoroquinolones
from treatment of gonorrhea. N. gonorrhoeae will then become known as a “superbug” due to
exclusions of penicillin, tetracycline, and fluoroquinolones from treatment guidelines (Unemo et al.,
2016). Resistance strains of ciprofloxacin remain high globally.
Azithromycin, a synthetic derivative of erythromycin, was developed in 1980 and used to
treat gonococcal infections. Like many of the other antimicrobials, gonorrhea quickly developed a
resistance to azithromycin in the mid-to-late 1990s. Resistance strains emerged first in Latin
America, then to many others such as England, Italy, China, and the U.S. (Unemo et al., 2016). As of
today, azithromycin is not recommended for monotherapy treatment of gonorrhea; however, it is
recommended in dual-therapy along with ceftriaxone.
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The ESCs are the most common and effective cephalosporins used to treat gonorrhea along
with injectable ceftriaxone and an oral administration of cefixime. Resistance to ESCs has emerged
over the last decade with initial patterns appearing in Japan and subsequently other countries around
the world (Unemo et al., 2016). The first cefixime-resistant strain to gonorrhea was isolated in 1995
in Kanagawa, Japan, and will rapidly increase to a resistance level of 57.1% in 2002 (Unemo et al.,
2016). Treatment failures as a result of clinical resistance to cefixime were documented from 19992001 in Japan. Japanese treatment guidelines for uncomplicated gonorrhea were updated in 2006 to
exclude oral ESCs and the new recommendations included intravenous ceftriaxone and cefodizime
as well as intramuscular spectinomycin.
Over the last decade, there has been an increase in resistance and reduced susceptibility to
ESCs worldwide (Unemo et al., 2016). There are three countries (Kyoto, Japan; Quimper, France;
and Catalonia, Spain) that have identified the first strain of extensively drug-resistant (XDR) N.
gonorrhoeae. The NG-XDR strains showed a high-level of resistance to ESCs and were also
resistant to all other therapeutic gonorrhea antimicrobials (Unemo et al., 2016). Due to an increase in
reduced susceptibility of cefixime in treating gonorrhea, CDC revised its treatment recommendations
in 2016 to include dual-therapy with gentamicin intramuscularly plus azithromycin orally and
gemifloxacin plus azithromycin, both orally (Vicentini et al., 2019).

Evolution of Surveillance Methods
The number of antimicrobial drugs for treatment of gonorrhea is rapidly declining and
monitoring resistance trends is critical to public health and global health security. The organism’s
ability to acquire resistance to antimicrobials has made it complicated to treat and control. In order to
maintain adequate first-line treatment options, it is important that surveillance of antimicrobial
resistance N. gonorrhoeae be conducted both domestically and internationally. To control the
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upward trend in AMR-NG, it is essential to conduct targeted surveillance of new resistance patterns
to grasp an understanding of risk factors and transmission within sexual networks.
The economic burden caused by gonococcal infections has made it difficult for many
countries to implement surveillance programs and improve laboratory diagnostics for gonorrhea. As
a result, many countries use syndromic surveillance to monitor these trends which is difficult to
interpret given that other diseases or STDs, such as chlamydia, may share similar symptoms (Weston
et al., 2017b). For the purpose of reducing the incidence of gonococcal infections and obtaining
accurate epidemiological data for implementing prevention initiatives, syndromic surveillance makes
it difficult to compare data due to inconsistencies in reporting. In order to combat AMR-NG and
eliminate the threat to global health security, it is imperative that countries have the ability to link
epidemiological and lab information to better understand the trends and risk factors within their
population. Syndromic surveillance should be replaced with a more high-quality surveillance system
with an infrastructure that can support the collection of accurate epidemiological information and lab
testing for gonorrhea.
The GISP was established in 1986 to monitor antimicrobial trends in the U.S. and to provide
the rationale for the selection of gonococcal therapy (CDC, 2016). This sentinel surveillance project
analyzes the antimicrobial susceptibility profile of gonococcal isolates of the first 25 male patients
from sentinel sites spanning over 25 cities and health departments in the US (Melendez et al., 2018).
GISP has been extremely instrumental in capturing resistance patterns of gonorrhea and the
emergence and transmission of resistance among various classes of drugs over time. An annual
report is generated each year analyzing the epidemiology and laboratory data collected by GISP and
it highlights resistance profiles in key populations. The data generated from GISP has been used over
the years to inform gonorrhea treatment recommendations in 1989, 1993, 1998, 2002, 2006, 2007,
2010, 2012, and 2015 (CDC, 2016). Other similar country-based surveillance programs are the
Gonococcal Resistance to Antimicrobial Surveillance Programme (GRASP) in the United Kingdom,
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the Australian Gonococcal Surveillance Program, and European Gonococcal Antimicrobial
Surveillance Programme. All three programs monitor trends in susceptibility of antimicrobials in
treatment of gonorrhea but may differ in their methodology. Each program also utilizes data
generated from their surveillance country to determine local treatment guidelines (Weston et al.,
2017b).
Globally, AMR-NG trends are monitored via the WHO Gonococcal Antimicrobial
Surveillance Program (GASP) which was established in 1992 to inform national, regional, and global
treatment guidelines. Each participating country within a given region provides susceptibility data to
its WHO regional office (Weston et al., 2017b). The challenge with this framework is that some
regions lack reports because countries in resource-poor settings have both financial and laboratory
restrictions that impact their ability to report. For example, in 2014, the WHO European Region
accounted for a majority of the GASP reports with 24 countries reporting versus two countries in the
African region and only one country in the Eastern Mediterranean Region (Weston et al., 2017b).
Interpretation of global trends using GASP data are also challenging given the inconsistency in
reporting by countries with only 46% stating AMR testing was conducted for gonorrhea in the past
five years. Also, demographic, behavioral, and clinical data are not routinely collected by GASP
countries so there are limitations in fully assessing risk factors associated with AMR-NG.
Improvements need to be made to global surveillance programs in order to strengthen the monitoring
of AMR-NG, especially in resource limited countries who have the most burden of disease.
In 2013, CDC released a report titled “Antibiotic Resistance Threats in the United States”
which highlighted AMR-NG as one of the most urgent threats in the U.S. (CDC, 2016). This report
led the White House to call for the prevention, detection, and control of antibiotic resistance, thereby,
establishing the National Strategy to Combat Antibiotic-Resistant Bacteria (CARB) in 2014 (CDC,
2016). Funds from CARB were used to establish the Antimicrobial Regional Laboratory Network in
2016 to provide culture-based susceptibility testing and genomic sequencing of gonorrhea isolates
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across seven regional public health laboratories (CDC, 2016). In 2017, CDC expanded GISP to
extend gonorrhea surveillance beyond urethral isolates to evaluate the burden of AMR-NG in
women, particularly assessing trends in non-urethral isolates (i.e., pharyngeal, rectal, and
endocervical isolated; CDC, 2018a).
The 2013 CDC report also led to a collaboration between WHO and CDC in 2015 to
enhance global health security and antimicrobial stewardship through the development of the
Enhanced Gonococcal Antimicrobial Surveillance Program (EGASP). EGASP aims to 1) utilize
standardized sampling and laboratory methods to monitor trends in antimicrobial susceptibility to
gonorrhea among sentinel sites and reference laboratories; and 2) improve the quality, patterns in
significant populations that are at higher risk for AMR-NG in order to inform treatment guidelines
and policy. EGASP collects behavioral and clinical data from each participant enrolled to include
demographics, prior antibiotic use, sexual behavior history, and treatment (Weston et al., 2017b).
Bangkok, Thailand was the first to implement EGASP in 2015 with two sentinel sites and two
reference labs. The goal of EGASP is to include at least ten sentinel-enhanced countries across all six
WHO regions. Improving surveillance on a global scale will allow for a more robust surveillance
system that can assist with developing evidence-based treatment guidelines that may also make more
treatment options available when resistance patterns differ country by country.

Health Disparities in Gonorrhea Epidemiology
Disparities in the epidemiology and treatment of gonorrhea are persistent with the gaps in
health determinants (i.e., race/ethnicity, income, access to healthcare, health behaviors, and other
social determinates of health) also found in other health conditions (CDC, 2019a). Health disparities
can be described as preventable differences in the burden of disease, injury, violence, or
opportunities to achieve optimal health that are experienced by socially disadvantage populations.
The WHO’s definition of social determinants of health are conditions in which individuals are born,
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grow, live, work, and age, including the health care system (Frieden & CDC, 2013). Research
demonstrates that some racial or ethnic minority groups have a higher rate of STDs in comparison to
their white counterparts (CDC, 2019a). For example, gonorrhea prevalence was 7.7 times higher
among Blacks than in Whites in 2018. There are approximately 19 million new cases of STDs that
occur annually in the U.S., and of those, people between the ages of 15 and 24 years make up about
50% of all cases (CDC, 2019a).
The incidence of AMR-NG in MSM is higher than reported cases in women and men who
have sex with women only (MSW). In order to reduce disparities in populations at the highest risk of
gonorrhea and AMR-NG, it is critical that we gain an understanding of the differences that exist in
these populations as it relates to health outcomes and health determinants. STD health equity can be
accomplished when all Americans have an equal opportunity to healthier sex outcomes in absence of
their race, ethnicity, age, income, sexual identity, and disabilities.
The rates of gonorrhea and other STDs differ in some racial minority or Hispanic groups in
comparison to the rates among Whites as a result of various health disparities. Some of these
disparities that correlate with race and Hispanic ethnicity and overall health status are poverty and
insurance coverage, income, employment, and educational level (CDC, 2019a). As shown in Figure
6, rates of gonorrhea among Blacks are at least 50% higher than rates of gonorrhea in other racial
groups. In 2017, the poverty rate for Blacks was 21.2% in comparison to 8.7% in Whites and 18.3%
in Hispanics (CDC, 2019a). When a population lacks the ability to afford basic necessities and life
essentials, they often times have difficulty in obtaining health insurance, which in turn, impacts their
ability to access quality health care. Access to and routine use of quality health care will help this
population to utilize sexual health services to include STD prevention and treatment. In instances
where healthcare is readily available, racial and ethnic minorities still face disparities as a result of
fear and distrust of health care facilities (i.e., Tuskegee Syphilis Study). Past negative encounters
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may influence one’s ability to seek care and could also be attributed to language barriers, social and
cultural discrimination, provider bias, and other negative perceptions (CDC, 2019a).
Figure 6
Gonorrhea—Rates of Reported Cases by Race/Hispanic Ethnicity, United States, 20142018 (CDC, 2019a)

The incidence and prevalence of overall STD cases suggest that adolescents and young
adults between the ages of 15-24 years acquire half of all new STD cases (CDC, 2019a). As shown
in Figure 7, rates or reported gonorrhea for females were highest among those aged 20-24 years and
15-19 years (CDC, 2019a). In males, the age group with the highest rates of gonorrhea were 20-24
years followed by 25-29 years. In assessing disparities across age categories, adolescents and young
adults are more susceptible to STD infections because of behavioral, biological, and cultural reasons.
Peer norms and media influences can drive behaviors in this age category and encourage risk-taking
sexual activities. In regard to access to health care, adolescents experience barriers that include an
inability to pay, conflict of clinic hours with school and work schedules, lack of transportation to
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clinics, long waiting times, embarrassment associated with seeking STD services, confidentiality
concerns (i.e., fear that parents will receive notification in mail for services), and methods of
specimen collection (CDC, 2019a).
Figure 7
Gonorrhea – Rates of Reported Cases by Age Group and Sex, United States, 2018 (CDC, 2019a)

In contrast to women and men who only have sex with women, men who have sex with men
(i.e., gay, bisexual, and other MSMs) have a higher incidence of STDs (see Figure 8; CDC, 2019a).
Disparities that exist in sexual orientation are connected to the increased frequency of sexual
behaviors that transmit STDs and HIV and sexual network characteristics. Factors that contribute to
these disparities and STD exposure are the number of lifetime or recent sex partners, rate of partner
exchange, and frequency of sex without condoms (CDC, 2019a). MSM sexual networks and
increased sexual risk behavior are also characterized with interconnectedness and concurrency of sex
partners, high prevalence of STDs, stigma (i.e., verbal harassment, discrimination, or physical
assault), and limited access to healthcare. Within the general MSM disparities, racial minority and
Hispanic MSM, young MSM, and those in lower income areas also have a higher burden of STDs
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overall. MSM display a higher rate of antimicrobial resistance to azithromycin and ceftriaxone in
comparison to MSW, as shown in Figure 8 (CDC, 2019a).
Figure 8
Neisseria gonorrhoeae– Percentage of Urethral Isolates with Elevated Minimum Inhibitory
Concentrations (MICs) to Azithromycin* and Ceftriaxone by Sex and Sex of Sex Partners,
Gonococcal Isolate Surveillance Project (GISP), 2009-2018 (CDC, 2019a)

Sexual Behaviors and Drug Use and Increased Risk of Gonorrhea and Other STIs
Risky sexual behavior, such as having sex for drugs/money, and injection and non-injection
drug use are often times associated with an increase in the risk of HIV and STIs due to high numbers
of sex partners and inconsistent condom use. In a study that analyzed the sexual health of male sex
workers (MSWs) in England, MSWs had a higher prevalence of HIV/STIs and were more likely to
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have reinfections than other male clinic attendees (McGrath-Lone et al., 2014). MSWs were also
more likely to be men who have sex with men, twice as likely to be diagnosed with gonorrhea
(MSM, 57.0% vs 14.8%, p<0.0001), and more likely to have reinfection of chlamydia and gonorrhea
than other male attendees (8.8% vs 3.6% and 14.1% vs 4.8% of those infected respectively, p<0.001)
(McGrath-Lone et al., 2014). Another study that observed correlations of HIV/STI, demographic and
drug use of male clients of female sex workers (FSWs) found that being paid for sex was
significantly associated with testing positive for HIV/STIs (Wagner et al., 2013). Both clients of
MSWs and FSWs commonly use alcohol and drugs (Wagner et al., 2013). Injection drug use in the
past four months was reported by almost half of the drug-using clients in the Wagner et al. study, and
the injection drug users were three times more likely to have sex for money during that period. In
Australia, 51% of MSWs reported that using alcohol or drugs during commercial sex encounters
(Wagner et al., 2013). Injection drug use was reported by 16% of MSWs in Madrid, Spain (Wagner
et al., 2013).

Policy Implications of AMR-NG in the United States
The threat of untreatable gonorrhea is becoming more of a reality as AMR limits treatment
options. A lack of funding for research and new drug development, insufficient surveillance
coordination, and failure to implement policy changes to protect the stewardship of antimicrobials
are all attributable to this concern. The WHO has rated N. gonorrhoeae among the “High Priority”
pathogens for research and development of new antibiotics in February 2017. Likewise, the U.S.
CDC has listed it in the top “Urgent Threat” category of 18 drug resistant threats in the U.S. (Alirol
et al., 2017). Gonorrhea is not usually considered a deadly disease; however, it poses a major threat
to the public’s health due to the widespread of infections, the significant cost on healthcare for
countries, its impact on women and their babies, and the rapid pace in which it has developed
resistance to antibiotics (Alirol et al., 2017). There’s a smaller pipeline for developing new drugs for
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gonorrhea which also amplifies the public health threat of untreatable gonorrhea given the upward
trend in resistant patterns.
Current AMR-NG surveillance activities in the U.S., conducted by GISP, focus primarily on
men, but recent enhancements in 2017 include women and extragenital. The data generated by GISP
only reflects the populations presenting to specialty STD clinics; hence, the sampling method does
not consider gonorrhea in private clinical settings and other non-STD clinic settings where those
most at risk of AMR-NG attend (Kirkcaldy et al., 2016). Another factor unique to GISP’s
methodology is the oversampling of the western region to quickly identify emerging resistance
trends. This strategy is effective in monitoring new trends in the regions where resistance tends to
emerge but may also overestimate the national prevalence of gonorrhea. Other strategies or
susceptible populations that may be missed in GISP include sexually active women, contact tracing
and sex partner linkage, those in low-income areas with limited access to care, countries of travel,
and screening of MSM at anatomic site after exposure.
In order to effectively combat and prevent future infections of AMR-NG, systems must be in
place for rapid investigation, contact tracing, network analysis, new and timely diagnostic test, and
funding to support the antimicrobial stewardship initiatives. In 2016, CDC was approved for $160
million additional funding for implementation of task identified in the CARB (Kirkcaldy et al.,
2016). This funding has allowed CDC to make plans to build capacity to rapidly detect and respond
to AMR-NG in up to nine U.S. counties in hopes that state and local partners will be able to slow
down the transmission of AMR-NG due to rapid identification of resistant infections. More timely
and tailored gonorrhea treatment can be provided with the development or use of well-validated
molecular assays for identifying susceptibility of antimicrobials. CDC has also applied these funds to
initiating molecular detection of gonorrhea. Physicians and public health professionals can utilize
risk factors to normalize and increase gonorrhea screening through Nucleic Acid Amplification Test
(NAAT). NAAT is a great tool for screening and diagnostic testing but it lacks the capacity to
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culture bacteria and prevents our ability to accurately track AMR-NG (Kirkcaldy et al., 2016). The
overall goal is to identify feasible and affordable methods for identifying AMR-NG so that it can be
accessible in resource-limited areas. From a global and international travel standpoint, it would be of
benefit to provide travel information that notifies travelers beforehand of possible risk in a given
country. Likewise, we should include more detailed travel information in risk assessments.
The best strategies for reducing the incidence and morbidity of AMR-NG are to continue
improving surveillance activities, implement policies that govern the use and prescription of
antimicrobials in clinical settings, develop new antimicrobials, and prevent transmission. The 2015
recommendations for treatment of AMR-NG and gonorrhea in general was dual-therapy with two
powerful antimicrobials, ceftriaxone (intramuscular) and azithromycin (orally). Policies need to be
implemented to limit the use of antimicrobials and to hold physicians accountable for
overprescribing. Monitoring prescription practices and potentially penalizing clinicians for over
prescribing. In developing new drugs, it may also be of benefit to design an antimicrobial that is only
used in human versus animals or other settings. This approach will help to preserve the stewardship
of new antimicrobials. If policies were in place to limit the use of current supply while we developed
new treatment options, then efforts to control and prevent future infections of gonorrhea will be more
attainable.

Practitioner Practices and Treatment Compliance
Practitioners play a major role in the prevention and treatment of gonorrhea. Their
knowledge of emerging antimicrobial resistance strains and adherence to changes in treatment
guidelines are essential in improving the appropriateness of antimicrobial use for treatment of
gonorrhea. A survey of primary care physician practices in prescribing antimicrobials for treatment
of uncomplicated male gonococcal urethritis was conducted in France (Falchi et al., 2011). In this
study, findings showed that of the 327 general practitioners (GPs) that were surveyed, only 66 GPs

41

(20%) correctly co-prescribed antimicrobials per the recommended first-line treatment of coinfections with N. gonorrhoeae and C. trachomatis (Falchi et al., 2011). The correct treatment
regimens were only prescribed for one-third of the cases. Another study that assessed compliance
with treatment guidelines in Estonia found that 48.6% of the 425 patients treated for gonorrhea were
not treated per guidelines (Tisler-Sala et al., 2018).
Falchi and colleagues (2011) also evaluated knowledge and other factors that influence the
prescribing practices of these practitioners. In accessing the GPs knowledge about fluoroquinolone
resistance of gonorrhea, only 84 (26%) reported that they were aware of the high rate of resistance in
France. Similarly, only 25% reported knowing that French treatment guidelines existed (Falchi et al.,
2011). General practitioners with 10 years or less time in practice were more likely to prescribe
antimicrobials according to the first-line treatment guidelines and were also more informed of
fluoroquinolone resistance than those with more than 10 years of experience (Falchi et al., 2011).
Overall, the study noted that findings were in alignment with previous studies which showed an
inverse relationship between years in practice and quality of care. Those that have been in practice
longer were at risk of providing a lower quality of care than their younger counterparts (Falchi et al.,
2011). Some of the reasons for not adhering to treatment guidelines could be due to barriers in
patient’s access to injectable ceftriaxone, large volume of biomedical information and a lack of time
to learn new developments, and the electronic dissemination of recommendations posing a barrier for
older practitioners.
Properly treating gonorrhea and other STIs as recommended will assist in reducing
transmission, severe disease complications, and antimicrobial resistance. Causes of antimicrobial
resistance can be associated with having multiple episodes of the same infection, a failure in
treatment, non-compliance in treating the STI, and a patient’s failure to adhere to prescription
regimens (Tisler-Sala et al., 2018). Some physicians may provide a different prescription for patients
with repeat infections of a particular disease as well (Tisler-Sala et al., 2018). Tisler-Sala and
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colleagues (2018) found that 14% of all of the prescriptions in the study were associated with
repeated treatment episodes of the same infection within the study period. Some ideas for ways to
improve practitioners’ compliance with STI treatment guidelines will be to explore new methods for
promoting the guidelines to the doctors, monitor adherence to guidelines more periodically, and
leverage electronic medical platforms to provide reminders and popups when doctors are inputting
prescriptions.

Conceptual Framework: Socio-Ecological Model
A conceptual framework may not fully describe the reality when using quantitative data, but it is
important to have a guide for why this work is relevant to the study population. While a theory is not
directly applicable to this study, the socio-ecological model can be used to identify solutions for
reducing the effects of AMR-NG among at-risk populations in the US. The socio-ecological model
observes interactions of individuals with the people, organizations, and community in which they are
affiliated with. The model consists of five levels: individual, interpersonal, community,
organizational, and public policy/enabling environment (see Figure 9; Lee et al., 2017). The socioecological model is most applicable to this study because it accounts for a broad range of
perspectives with interaction and reinforcement across the five levels. SEM offers a great approach
for assessing level-specific influences in order to alter the attitudes, behavior and beliefs of
individuals to improve awareness and treatment of gonorrhea among disadvantaged populations and
reduce the transmission of AMR-NG.
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Figure 9
The Socio-Ecological Model (Lee et al., 2017)

Individual. The characteristics and traits of an individual that influences behavior makeup
this level. Examples of some of these factors are age, level of education, sexual orientation, and
socio-economic status (Project, 2017). An individual’s knowledge and understanding of a disease
outcome can affect their perspective on preventive measures and can also impact their behavior and
attitude towards risky behaviors. Likewise, individuals in low-income areas will have limited access
to healthcare and are at higher risk of adverse health outcomes.
Attitude towards and awareness of antibiotic usage. Education around the topic of
antimicrobial resistance is essential for behavior change since public knowledge is low and many
individuals don’t believe that they play a role in AMR (Fletcher-Miles, Gammon, Williams, & Hunt,
2020). The perception of risk for AMR-NG is low in some populations because in order to change
and sustain behaviors that would benefit AMR management, individual ownership needs to be
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generated in at-risk populations along with tailored education and the reinforcement of social
learning.
Interpersonal. The social networks and relationships that a person has with other
individuals can also impact their behavior. Key players in the interpersonal level of this model are
family, friends, and social traditions (Project, 2017). People acquire norms through their ties in social
networks (McLeroy, Bibeau, Steckler, & Glanz, 1988). Stigmatization and shame surrounding STDs
can also discourage STD testing and treatment. Stigma can be defined as the one’s fear that having a
particular trait or outcome will make the subject to negative societal attitudes and discrimination
(Morris et al., 2014). Social media and other social networking applications may also influence riskrelated sexual behavior as it allows for individuals to connect with others more efficiently and at a
higher frequency (Carmack & Rodriguez, 2020). Inversely, social media can also be used for health
education interventions targeting youth and young adults to alter their perceptions and sexual
behaviors in an effort to reduce STD transmission.
Societal norms. An individual’s attitude and behavior towards preventive measures, such as
condom use and STD screening, can be influenced by their partner and social networks. The fear of
discrimination and negative societal attitudes towards STDs can prolong the time in which an
individual seeks care or treatment. It can also impact the likelihood of someone discussing riskybehaviors and exposures with their health-care provider or partner (Morris et al., 2014). African
American men are less likely to perform a self-examine or get screened for infectious diseases, often
times are delayed in seeking care after symptom onset and are less likely to access healthcare
services (Morris et al., 2014).
Influence of social media and social networks. Many youths under the age of 24 years use
the internet and social media and networking sites frequently to access information and connect with
others. As it pertains to sexual behavior and sexual health, these platforms can be used as a method
to connect quickly with others for sexual exchanges or can be used to educate youth about safe
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sexual practices and/or connect them to clinical services. Social media can be used in the short term
to facilitate preventive measures in the reduction of condom use in high-risk youth (Bull et al.,
2012).
Community. The third level of the model acknowledges the social relationships that occur
between various networks in organizations and institutions. In observing the influence of community
on an individual’s behavior, we must identify the characteristics of the community that are
attributable to the outcome of interest. Partnerships with agencies, churches, neighborhoods, and
other mediating structures can influence change within communities (Golden & Earp, 2012). The
various entities that make up a community can pool together resources to improve community health.
Culture standards of practice. Understanding how different populations perceive the risk of
disease transmission is critical in influencing risk-behaviors. In the United States, minority groups
are more likely to have disbelief in reported disease burden or prevalence in their community due to
various political and historical events (Reuter et al., 2018). Some individuals may not feel as though
they are impacted by the disease due to a lack of exposure to individuals with it. When community
prevalence is low, beliefs or concerns of infection may also be low. Culture stigma can play a role in
STI testing practices, self-reporting of disease, partner notification, and partner-delivered treatment
(Morris et al., 2014).
Organization. Organizations are instrumental in reaching various sectors of people within a
community. This level of the model helps to enforce regulations and restrictions that are determined
by behaviors (Project, 2017). An example of how organizational structure and regulations can
directly impact health outcomes is the implementation of smoking regulations that prohibit and/or
confine smoking to a designated area around workspaces and restaurants. Organizations can also
influence health outcomes through effective communications about safe health practices coupled
with health services and healthcare benefits.
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CDC STD Treatment Guidelines. The guidelines provided by CDC for treatment of STDs
can influence the prescribing practices of physicians and STD clinics. The ability of healthcare
organizations to implement changes in the guidelines can have a direct or indirect impact on drug
efficacy and resistance patterns. Also, funding provided by the federal government to implement
programs and provide additional resources to the state and local entities can help to target at-risk
populations.
Policy/Enabling Environment. The final and more broad level of SEM encompasses
policies and laws at local, national, and global levels (Project, 2017). Preventive efforts are governed
by conducting research on the transmission of STDs and establishing more effective ways to
intervene to prevent and control the spread. This level also affects a larger portion of the population
through creating and enforcing laws. When it comes to policies for STD prevention, there aren’t
many mandated laws, however, the use and prescribing of antimicrobials in both humans and
animals can be controlled through more regulatory means.
Socio-ecological Model and AMR-NG. In 2018, the burden of sexually transmitted
diseases caused by N. gonorrhoeae was over 500,000, thereby occurring at a rate of 179.1 cases per
100,000 people (CDC, 2019a). With such a high prevalence of disease, there is also a great deal of
disparities in the distribution of infections by race/ethnicity, geographic region, and sexual
orientation (Tuite et al., 2018). In the United States, the gonorrhea epidemic is highly concentrated at
the community level in young, black heterosexuals and men who have sex with men. Among the
four regions in the United States, the South had the largest rate of gonorrhea in 2018. Interactions
across the individual, community, and organization levels often increase the risk of AMR-NG in a
given population. For example, socioeconomic status, access to quality care, and discrimination are
some of the social determinants of health that contribute to the major burden that gonorrhea has in a
given community (CDC, 2019a). Individuals in communities with a high prevalence of gonorrhea are
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at a greater chance of engaging with an infected partner at every sexual encounter in comparison to
others in low-risk areas.
The social and economic conditions in minority communities will need to be fully assessed
in order to address the systematic inequities in the burden of disease (see Table 1). Historically,
Blacks have had a great deal of negative health encounters and cultural discrimination that have led
to fear and distrust in health institutions (i.e., Tuskegee Syphilis Study). This impacts their ability to
seek care when needed as well. Blacks are also more impacted by poverty having a poverty rate of
21.2% in 2017 in comparison to their White counterparts with only a poverty rate of 8.7% (CDC,
2019a). Poverty rates directly correlate with income, employment, insurance status, and educational
fulfillment.
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Table 1
Socio-Ecological Model for Assessing Risk Factors of Antimicrobial Treatment per CDC STD
Treatment Guidelines
Level
Individual/Intrapersonal: The
individual characteristics that
influence behavior, including
knowledge, skills, motivation,
and personality traits

Examples of Contributing Factors

Variables

•
•
•
•
•
•
•
•

Skills
Knowledge
Attitudes
Sexual Orientation
Biology
Motivation
Gender Identity
Spirituality

• Race/Ethnicity
• Age
• Sexual
Orientation
• Previous history
of gonorrhea
• Previous history
of antibiotic use

Interpersonal: Relationships
with others and effects on social
identity

•
•
•
•
•
•
•

Social Support
Social Networks
Associations
Culture
Peer Influence
Family Environment
Emotional Support

• Sex for
Money/Drugs
• Injection Drug
Use
• Non-injection
Drug Use

Organizational/Institutional:
Rules and regulations of
organizations and institutions
that can impact behavior

•
•
•
•
•
•

Incentives Policies
Confidentiality/Privacy
Rules
Stigma
Referral Systems
Parental Consent Regulations

• Antimicrobial
Treatment per
CDC Guidelines

Community: Availability and
location of resources that
promote health, social networks,
and social norms

•
•
•
•
•
•

Transportation
Health Care Services
Poverty Tolerance
Social/Cultural Norms
Recreation Facilities
Mobilization

• Region

Policy: Local, state, and federal
policies and laws that impact
health

•
•
•
•
•
•
•
•

Funding and Resources
Cultural Norms
Curfews
Gender Equity
Drinking Age
Racial and Ethnic Equity
Infrastructure
Political Priorities

• N/A
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Chapter Summary
Gonorrhea is the second most commonly reported notifiable disease in the U.S. in 2018, and
is associated with high morbidity and socioeconomic significances, thereby posing a major public
health threat worldwide. Although it is currently treatable, there are concerns for the potential
emergence of untreatable gonorrhea due to increased trends in antimicrobial resistance. CDC’s
recommendations for the treatment of gonorrhea have changed over time in response to the emerging
resistance patterns to all classes of antimicrobials. Surveillance activities are very essential in
identifying risk factors in populations with the highest risk. Targeted interventions and countryspecific guidance is necessary to increase the number of drugs available while also containing
transmission. Therefore, in order to control AMR-NG, efforts will need to focus on improved
surveillance, development of policies, preventive measures, enhanced diagnostics testing, and
effective antimicrobial treatment.
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CHAPTER 3
METHODOLOGY
Overview
This chapter details the methods used to conduct this study. The chapter begins by
reintroducing the purpose of the study and research question, followed by methodology describing
the variables that will be used in the analysis, and a description of the study sample. A brief history
of the use of the GISP follows, including a description of the instrumentation and data collection
methods. Finally, the chapter closes with details on how the data will be analyzed in this study, any
ethical considerations that accompany GISP data use, and limitations to the GISP dataset.

Purpose Statement
The purpose of this study is to identify risk factors that are associated with and trends in
antimicrobial susceptibility patterns that exist in strains of N. gonorrhoeae identified through GISP
participants following the implementation of the 2012 and 2015 CDC STD treatment guidelines. The
empirical evidence will help to monitor the emergence of AMR-NG, inform polices around the use
of antimicrobials, evaluate treatment guidelines, and to target interventions to populations with the
highest risk.

Research Questions and Hypotheses
The research questions and hypotheses that guide this study are:
Question 1: What trends in antimicrobial susceptibility patterns exist in strains of N. gonorrhoeae
among men who received the recommended treatment per STD Treatment Guidelines versus those
who received alternative regimens?
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•

Hypothesis 1A: Men who received alternative treatment regimens for Neisseria
gonorrhoeae are more likely to have resistance to multiple drugs than those treated per
treatment guidelines.

Question 2: What risk factors are associated with having received treatment per STD Treatment
Guidelines versus not?
•

Hypothesis 1B: Black men are more likely to have not received the recommended treatment
compared to men in other race categories.

•

Hypothesis 2B: Men between the ages of 15-24 are more likely to receive alternative
regimens than other age categories.

•

Hypothesis 3B: Men who have sex with men are more likely to have received an alternate
method of treatment compared to men who have sex with women only.

•

Hypothesis 4B: Men with previous confirmed episodes of gonorrhea in the past year are
more likely to have received the recommended treatment regimen than men with no prior
episodes.

•

Hypothesis 5B: Men who have a history in the previous 12 months of risky sexual behavior
or drug use are less likely to have received the recommended treatment.

•

Hypothesis 6B: Men in the South are more than likely to be treated with alternative
regimens than those in other regions.

Research Methodology
The quantitative analysis for the observational study of this research assesses the relationship
of binary and categorical variables related to risk factors and antimicrobial susceptibility patterns in
Neisseria gonorrhoeae. Given that secondary data are used to conduct this analysis, there is no
theoretical framework that completely guides the study. However, in the previous chapter, some
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conceptual frameworks guiding this study were discussed, including the social-ecological model
which is nuanced in the selection of variables (see Chapter 2 for explanation).

Study Sample
The target population for GISP is the first 25 male patients presenting with symptomatic
urethritis to a sentinel site each month. Symptomatic urethritis can include discharge, dysuria,
urethral stinging/itching and penile tip irritation. Urethral specimens are collected from these 25 men
and sent to the Antibiotic Resistance Lab Network (ARLN) for further testing. Sentinel sites may
have variability in the number of isolates sent on a month-to-month basis, but the overall goal is for
each sentinel site to send at least 300 isolates per year. The samples are selected systematically at the
sentinel sites and are solely based on symptom presentation for inclusion in the project. There are
approximately 25-30 GISP sentinel sites that contribute to GISP over the given time period.
In this study, the demographic, clinical, and behavioral data, as well as antimicrobial
susceptibility data, are obtained from the GISP database. The study sample is a subset of the GISP
population which only includes men who received dual/combination therapy for treatment between
2012-2018. The total population for GISP in 2012-2018 is 52,578, men with gonorrhea. The data
were obtained from the study population by using non-probability sampling and directly selecting
participants by removing those with null for TRMT1 or TRMT2. The study sample size is 37,157
men. Risk factor associations and resistance trends were assessed by conducting a bivariate and
multivariate analysis across all variables over the specified time-period.

Instrumentation
The GISP was established in 1986 in response to acquired resistance of gonorrhea and is a
collaborative effort between CDC Division of STD Prevention Surveillance and Data Management
Branch, the Laboratory Reference & Research Branch; Antibiotic Regional Laboratory Network
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regional laboratories; and selected U.S. public health STD programs and associated STD specialty
care clinics and local public health labs (sentinel sites). Data generated by GISP provide CDC with
contextual information necessary to revise and develop STD treatment guidelines. Previously, these
data were used for CDC’s STD Treatment Guidelines to inform gonorrhea treatment
recommendations in 1989, 1993, 1998, 2002, 2006, 2007, 2010, 2012, and 2015. GISP is directly
funded through the Epidemiology and Laboratory Capacity Program.
For years 2012-2017, both clinical and demographic data were submitted electronically
using Form one of the secure GISP web-based application. In 2017-2018, data are collected for GISP
using a manifest generated in Microsoft Excel that collects isolate information for lab purposes, and
a second manifest to collect clinical and demographic data. The manifest allows direct data entry by
sites or a copy and paste option if a site is exporting data from a local system. Data quality checks
are embedded in the Excel spreadsheet in order to generate an error report as the data entered is
assessed for mistakes. The lab manifest data elements, sent to the regional labs, include the patient
ID, specimen source, specimen collection date, gender, possible N. meningitidis, age, patient’s date
of birth, facility location, and GISP specimen ID. The data dictionary for the clinical and
demographic data elements are provided in Appendix A. The manifest is designed to collect data for
multiple projects; therefore, GISP sites are only required to complete data elements that is required
for GISP.
The antimicrobial susceptibility criteria used in GISP for 2018 are as follows:
•

Ceftriaxone, minimum inhibitory concentration (MIC) ≥0.5 μg/ml (decreased
susceptibility)*

•

Ceftriaxone, MIC ≥0.125 μg/ml (elevated MIC)*

•

Cefixime, MIC ≥0.5 μg/ml (decreased susceptibility)*

•

Cefixime, MIC ≥0.25 μg/ml (elevated MIC)*

•

Azithromycin, MIC ≥2.0 μg/ml (elevated MIC)*
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•

Ciprofloxacin, MIC ≥1.0 μg/ml (resistance)

•

Ciprofloxacin, MIC 0.125–0.5 μg/ml (intermediate resistance)

•

Penicillin, MIC ≥2.0 μg/ml (resistance)

•

Tetracycline, MIC ≥2.0 μg/ml (resistance)

•

Gentamicin (MIC values correlated with susceptibility and resistance have not been
established)*

The majority of these criteria are also recommended by the Clinical and Laboratory Standards
Institute (CLSI). As of December 2018, the CLSI criteria for resistance to ceftriaxone, cefixime,
gentamicin, and azithromycin and for susceptibility to azithromycin and gentamicin have not been
established for N. gonorrhoeae (CDC, 2019a).

Measures
The variables used to measure the association of resistance categories with treatment
practices were penicillin-resistance, tetracycline-resistance, cefixime-resistance, ceftriaxoneresistance, azithromycin-resistance, and multidrug resistance. Variables that were leveraged for
identifying patient characteristics and risk factors that may impact prescribed clinical practice to the
treatment guidelines were race, age, sex orientation, region, previous history of gonorrhea, any
antibiotic use during previous 60 days, history of giving or receiving drugs/money for sex in
previous 12 months, history of injection drug use in previous 12 months, and history of non-injection
recreational drug use (excluding alcohol) in previous 12 months. Treatment practices and
antimicrobial resistance patterns across regions was assessed measuring the association of the
resistance variables penicillin-resistance, tetracycline-resistance, cefixime-resistance, ceftriaxoneresistance, azithromycin-resistance, and multidrug resistance with region.
A total of eleven variables were constructed in order to measure associations outlined in
each research question and the hypotheses. The variable “AGECAT” was created to re-structure or
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group AGE into categories. The AGECAT variable included 9 categories with the groupings as
follows: 1= 1-19 years, 2=20-24 years, 3=25-29 years, 4=30-34 years, 5=35-39 years, 6=40=44
years, 7=45=49 years, 8=50-54 years, and 9=55+ years. The BLACKWHITE variable was
constructed using the RACEALL variable and included four groups: 1=White (RACEALL=5),
2=Hispanic (RACEALL=7), 3=Other (RACEALL=1, 2, 4, and 6) and 4=Black (RACEALL=3). The
decision to group race into four categories was determined as a result of having less than 5 records in
a cell when conducing the bivariate analysis. The variable ‘SexPartner’ was categorized from
‘SEXOR’ into a dichotomous variable (1=MSW, 2=MSM). Men that reported having sex with
women only (heterosexual) were categorized as ‘Men who have sex with women Only’ (MSW) and
men who identified as bisexual or homosexual were grouped as ‘Men who have sex with Men’
(MSM). Region was developed using the variable CLINIC and generated four categories: MW, NE,
S, W. Midwest (MW) included CLINIC values CHI, CLE, COL, IND, KCY, MIL, MIN, and PON.
Northeast (NE) Region included CLINIC values BOS, BUF, NYC, and PHI. The South (S) Region
included ATL, BAL, BHM, DAL, GRB, JAC, MIA, NOR, OKC, RIC, and WDC. The West (W)
Region included ANC, ALB, DEN, HON, LAX, LA1, LA2, LVG, ORA, PHX, POR, SDG, SEA,
SFO, and TRP.
Antimicrobial variables were reconstructed to create dichotomous variables that indicated
whether the isolate had resistance/elevated MIC to a given drug versus whether it was susceptible.
All variables were coded as ‘1’ for resistance or elevated MIC and ‘2’ for susceptible based on the
MIC breakpoints for the drug. For penicillin resistance (PEN_SUS), if the value for PEN was greater
than or equal to ‘2.0’ µg/ml then PEN_SUS was coded as 1, otherwise PEN_SUS=2. Tetracycline
resistance (TET_SUS) equals ‘1’ when TET has a value that is greater than or equal to 2.0 µg/ml,
otherwise TET_SUS=2. Elevated MICs in Cefixime (CFX_SUS) is equal to ‘1’ when CFX has a
value of 0.5 µg/ml or greater and CFX_SUS equals ‘2’ otherwise. Elevated MICs for Ceftriaxone
(CRO_SUS) is equal to ‘1’ when CRO is greater than or equal to 0.125 µg/ml and equals ‘2’ for
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values less than 0.125 µg/ml. Ciprofloxacin resistance (CIP_SUS) is equal to ‘1’ when CIP has a
value great than or equal to 1.0 µg/ml and equals ‘2’ when CIP is less than 1.0 µg/ml. Elevated MICs
for Azithromycin (AZI_SUS) is equal to ‘1’ when AZI is greater than or equal to 2.0 µg/ml and
AZI_SUS equal ‘2’ when AZI is less than 2.0 µg/ml. Multidrug resistance (MULTIRES) was
constructed by assessing whether an isolate was decreased susceptibility or resistant to more than 1
of the drugs.
The dependent variable ‘TreatGuid’ was generated using the primary treatment for
gonorrhea (TRMT1), the second antimicrobial used as a part of dual therapy for gonorrhea
(TRMT2), and the month and year of the clinic visit (YRMO). If a patient visited the clinic between
January 2012 and August 2012 and the primary treatment method was ceftriaxone (Rocephin) 250
mg or cefixime (Suprax) 400 mg and the second antimicrobial used was doxycycline
(Vibramycin)/tetracycline or azithromycin (Zithromax) 1 gm, then TreatGuid = ‘1’ (Yes), otherwise
TreatGuid = ‘2’. If a patient visited the clinic between September 2012 and June 2015 and the
primary treatment method was ceftriaxone (Rocephin) 250 mg and the second antimicrobial used
was doxycycline (Vibramycin)/tetracycline or azithromycin (Zithromax) 1 gm, then TreatGuid = ‘1’
(Yes), otherwise TreatGuid = ‘2’. If a patient visited the clinic between July 2015 and beyond and
the primary treatment method was ceftriaxone (Rocephin) 250 mg and the second antimicrobial used
was azithromycin (Zithromax) 1 gm, then TreatGuid = ‘1’ (Yes), TreatGuid = ‘2’ (see Table 2).
Appendix A provides a summary of how variables were operationalized for the present study.
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Table 2
CDC STD Treatment Recommendations 2010, 2012, and 2015
Date of Change
12/17/2010

CDC STD Treatment Recommendations
Dual treatment recommended regardless of CT infection
(Workowski et al., 2010)
Uncomplicated Gonococcal Infections of the Cervix, Urethra, and
Rectum
• Ceftriaxone 250 mg IM in a single dose OR IF NOT AN OPTION
• Cefixime 400 mg orally in a single dose OR
PLUS
• Azithromycin 1 g orally in a single dose OR
• Doxycycline 100 mg orally twice a day for 7 days.

8/10/12

6/15/15

Uncomplicated Gonococcal Infections of the Pharynx
• Ceftriaxone 250 mg IM in a single dose OR
PLUS
• Azithromycin 1 g orally in a single dose OR
• Doxycycline 100 mg orally twice a day for 7 days.
Cefixime no longer recommended as a first-line regimen for treatment of
gonococcal infections. If cefixime is used as an alternative agent, then the
patient should return in 1 week for a test-of-cure at the site of infection.
(CDC, 2012)
Doxycycline no longer recommended as part of dual therapy (Workowski et
al., 2015)
Uncomplicated Gonococcal Infections of the Cervix, Urethra, and
Rectum
• Ceftriaxone 250 mg IM in a single dose OR
PLUS
• Azithromycin 1 g orally in a single dose

Uncomplicated Gonococcal Infections of the Pharynx
• Ceftriaxone 250 mg IM in a single dose
PLUS
• Azithromycin 1 g orally in a single dose

58

Data Management
Once the site has collected the isolates and completed the lab and clinical/demographic
manifests, the documents are then provided to ARLN. A printed copy of the lab manifest is provided
with each isolate shipment that is sent to the ARLN lab. An electronic copy of the lab manifest is
provided to ARLN via a secured file transfer portal site on or before the day in which the
corresponding isolates are shipped. The submitting site is required to notify the point of contact at
the receiving lab via email that the manifest has been uploaded and the estimated time of arrival from
the shipment.

Data Analysis
The GISP data were retrieved in a comma-separated values (CSV) format and imported into
SAS 9.4 Software for analysis. The numbers and percentages presented in this paper are
unweighted. The susceptibility trends of antimicrobials were interpreted using criteria established by
the Clinical and Laboratory Standards Institute (CLSI). Antimicrobials in which no resistance criteria
have been established (i.e., cefixime, ceftriaxone, and azithromycin) were categorized as “reduced
susceptibility” when MIC values are higher than wild-type distributions (Kirkcaldy et al., 2016). The
prevalence of resistance patterns over time were assessed using means, medians, standard deviation
(SD), and proportions as necessary for the descriptive analysis. The Cochran-Armitage trend test was
used to see if the change in percentage of antimicrobial resistance for those that received treatment
per treatment guidelines versus not had a significant trend over the years. The characteristics of risk
factors were evaluated using bivariate analyses conducted by chi-square test, with a significance
level of p<0.05 and such test of bivariate association selects variables to be included to fit the
multivariate regression model. For multivariate analysis, a logistic regression model was used to
explore the relationships of the various risk factors with the outcome of interest, patient treated per
CDC STD guidelines versus not.
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Testing of Research Question 1 involved the bivariate analysis of the dependent variable
“TreatGuid” and independent variables: PEN_SUS, TET_SUS, CFX_SUS, CRO_SUS, CIP_SUS,
AZI_SUS and MULTIRES. The bivariate analysis was conducted using the ‘proc freq’ procedure in
SAS along with the ‘chisq’ feature. Drug resistance patterns that were deemed as statistically
significant from the p-value obtained from the bivariate analysis were included in the logistic
regression model.
Testing of Research Question 2 involved the bivariate analysis of the dependent variable
“TreatGuid” and independent variables: RACEFOUR, AGECAT, SEXPARTNER, HISTORY,
REGION, SEXWK, ANTIBIOT, IDU, and NONIDU. The bivariate analysis was conducted using
the ‘proc freq’ procedure in SAS along with the Chi-square test. Risk factors that were deemed as
statistically significant from the p-value obtained from the bivariate analysis were included in the
logistic regression model.

Ethical Considerations
GISP is periodically reviewed by the Office of the Associate Director of Science, National
Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, and CDC. The most recent review
took place in December 2016 and the project was determined to be surveillance and disease control
activities, and not human subjects’ research. Regarding data management, each of the sentinel site
laboratories maintains a log of all the GISP IDs generated and routinely shares this information with
the staff person responsible for extracting the clinical and demographic data for the patients.

Limitations
There are a few limitations to note in this study. The first is that surveillance conducted for
GISP is exclusively in STD specialty clinics, which may attract a different demographic than other
healthcare facilities. Secondly, this sample will not account for individuals diagnosed via a primary
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care physician or other routine doctor’s visit. Travel history, specifically the location, can also be a
risk factor for AMR-NG given that different resistance patterns may exist in other countries in
comparison to the U.S. The dataset used for this analysis does not provide information as to where a
case has traveled and therefore poses a limitation when understanding the risks associated with
international exposure. Another limitation is the variability in reporting of race and ethnicity across
reporting jurisdictions. Self-reporting bias is a limitation for some of the clinical variables.

61

CHAPTER 4
RESULTS
Overview
This quantitative study sought to answer the research questions: What trends in
antimicrobial susceptibility patterns exist in strains of N. gonorrhoeae among men who received the
recommended treatment per STD Treatment Guidelines versus those who received alternative
regimens? What risk factors are associated with having received treatment per STD Treatment
Guidelines versus not? The sample size used for the 2012-2018 GISP consisted of 37,157 culture
positive gonorrhea isolates for men receiving dual-therapy for treatment of gonorrhea. The data were
first analyzed to provide descriptive statistics. The data were then examined to uncover associations
between the independent and dependent variables using bivariate analysis and logistic regression
modeling. This chapter will provide the results of the analysis that answers the research and aims.

Sample Demographics
Reviewing the overall demographic data of the sample population in Table 3, we have a
good idea of characteristics that may or may not influence associations between the independent
variables and outcome. In assessing the race and ethnicity of participants in the sample, 59.3%
reported race as Black, 20.7% reported White, 14% accounted for Hispanics, and the remaining 6%
were either American Indians/Alaskan Natives, Asians, Native Hawaiians/Other Pacific Islanders,
Multirace, or Other/Unknown. Participants were on average 30.8 years old (SD=10.5) and age
ranged from one year to 84 years with a median of 28 years. Most participants were from the West
coast (38.1%) with close to 25% from both the Midwest and South and very few were from the
Northeast region (11%). Most of the men identified themselves as heterosexual (63%), and 37%
mentioned having sex with men (homosexual or bisexual). In reporting rather or not there was a
history of gonorrhea infection in the past 12 months, almost half of the study sample reported a
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history of gonorrhea infection. The majority of the sample had symptoms of urethral gonorrhea
minus only 3% who had none.
Table 3
Sociodemographic Characteristics of Study Participants, GISP 2012-2018
Baseline Characteristic

Race
American Indians/
Alaskan Native
Asians
Blacks
Native
Hawaiians/Pacific
Islanders
Whites
Multirace
Hispanic
Other/Unknown
Region
Northeast
Midwest
South
West
Sex orientation
MSM
MSW
Previous history of
gonorrhea a
Yes
No
Sex for drugs/moneya
Yes
No
Antibiotic usea
Yes
No
Injection drug usea
Yes
No
Non-injection recreational
drug use
Yes
No

Followed CDC
Treatment Guidance
N
%

N

Did Not Follow CDC
Treatment Guidance
%

Full Sample
N

%

102

0.3

7

0.3

109

0.3

701
20564
192

2.0
59.9
0.6

50
1084
10

2.3
50.0
0.5

751
21648
202

2.1
59.3
0.55

6856
410
4865
606

20.0
1.2
14.2
1.8

709
19
249
42

32.7
0.9
11.5
1.9

7565
429
5114
648

20.7
1.2
14.0
1.8

3888
9329
8446
12962

11.2
26.9
24.4
37.4

189
459
466
1083

8.6
20.9
21.2
49.3

4077
9788
8912
14045

11.1
26.6
24.2
38.1

12303
21980

35.9
64.1

1047
1113

48.5
51.5

13350
23093

36.6
63.4

17299
16228

51.6
48.4

1103
970

53.2
46.8

18402
17198

51.7
48.3

874
26938

3.1
96.9

77
1267

5.7
94.3

951
28205

3.3
96.7

2870
23755

10.8
89.2

166
1062

13.5
86.5

3036
24817

10.9
89.1

654
29434

2.3
97.8

67
1348

4.7
95.3

721
30782

2.3
97.7

8374
20958

28.6
71.4

443
932

32.2
67.8

8817
21890

28.7
71.3

Note. N=35757. Percentages are column percentages. Participants were on average 30.8 years old (SD = 10.5),
and participant age did not differ by condition. MSM=Men who have sex with men. MSW=Men who have sex
with women only. a Reflects the number and percentage of participants answering “yes” to this question.
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Behavioral risk factors were assessed in the study population by asking participants about
sexual practices and drug use. Very few men reported having previously exchanged sex for drugs or
money in the last 12 months (3%). Injection drug use was also uncommon (2.3%), but 28.7% of the
participants noted the use of non-injection recreational drugs in the previous 12 months. A total of
3,036 participants (10.9%) used antibiotics in the previous 12 months. On average, the men in this
study received treatment according to CDC STD treatment guidelines 95% of the time across most
factors.

Descriptive Analysis and Variable Selection
Bivariate analysis. The tables below were created for each research question and hypothesis
and represent the output generated from the bivariate analyses. A chi-square test was conducted to
test the association between each independent categorical variable and the dependent/outcome
variable of adherence to CDC STD treatment guidelines based on the antimicrobials prescribed. All
the cell frequencies were greater than 5 observations (see Table 4).
Table 4
Bivariate Analysis of Antimicrobial Susceptibility and CDC STD Treatment Guidelines: Results from
the Cochran-Armitage Trend Analysis
Variable

N

Penicillin-resistance

36822

Degrees of
Freedom
1

Z

p-value

0.09

0.9320

Tetracycline-resistance

36822

1

1.52

0.1279

Cefixime-elevated MIC

36822

1

-1.06

0.2911

Ceftriaxone-elevated MIC

36822

1

-0.12

0.9057

Ciprofloxacin-resistance

36822

1

3.56

0.0004*

Azithromycin-elevated
MIC
Multidrug Resistance

36822

1

1.59

0.1121

36822

1

2.70

0.0070*

Note. Number of observations = 36822, Number of Missing = 335, total N = 52,578. Z = Z Statistic.
Penicillin-resistance: MIC ≥ 2.0, Tetracycline-resistance: MIC ≥ 2.0, Cefixime-elevated MIC: MIC ≥ 0.25,
Ceftriaxone-elevated MIC: MIC ≥ 0.125, Ciprofloxacin-resistance: MIC ≥ 1.0, Azithromycin-elevated MIC:
MIC ≥ 2.0, Multidrug Resistance = 1 when resistant to more than one antimicrobial
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Bivariate analysis for antimicrobial susceptibility patterns. The bivariate analysis
conducted for Research Question 1 uncovered a statistically significant association between both
ciprofloxacin resistance (p = 0.0004) and multidrug resistance (p = <0.0001) gonorrhea with
adherence to CDC STD treatment guidelines (see Figure 10). The total number of participants with
complete data for the six drug fields were n=36822.
Figure 10
Percent of Ciprofloxacin-resistance and Multidrug-resistance Gonorrhea among Men Treated Per
CDC STD Guidelines Versus Those That Were Not, 2012-2018
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When reviewing the antimicrobial susceptibility trends among men who received treatment for
gonorrhea per CDC guidelines versus those who did not, we see an increase in resistance to
ciprofloxacin after 2015 among men who were not treated per CDC guidelines. Prior to 2015 the
difference between the two outcome groups varied. However, ciprofloxacin resistance in men not
receiving treatment per CDC guidelines was higher overall with the exception of years 2013 and 2015.
Multidrug resistance had a similar trend with resistance higher among men who were not treated
according to CDC guidelines across all years minus 2013 and 2015. Although not statistically
significant, susceptibility trends for tetracycline and penicillin among the outcome variable did not differ
much between the two groups. Some of the cells for the independent drug variables also had less than 5
observations when assessing the trends between the two outcome groups over time.
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Table 5
Survey: Trends of Antimicrobial Resistance Patterns by Adherence to CDC STD Treatment Guidelines, 2012-2018
Drug Resistance

2012

2013

2014

2015

2016

2017

2018

Total

n (%)

n (%)

n (%)

n (%)

n (%)

n (%)

n (%)

n (%)

668 (13.0)

688 (12.1)

753 (16.0)

754 (15.8)

883 (17.7)

737 (15.6)

616 (13.4)

5099 (14.7)

38 (15.4)

20 (9.6)

57 (16.4)

53 (15.1)

46 (18.1)

51 (16.8)

60 (12.4)

325 (14.8)

1191 (23.1)

1351 (23.8)

1177 (25.0)

1153 (24.1)

1114 (22.4)

1096 (23.2)

1201 (26.2)

8283 (23.9)

80 (32.4)

46 (22.0)

104 (30.0)

93 (26.5)

69 (27.1)

62 (20.5)

103 (21.2)

557 (25.4)

Followed guidelines

49 (1.0)

25 (0.4)

36 (0.8)

24 (0.5)

16 (0.3)

21 (0.4)

13 (0.3)

184 (0.5)

Did not follow guidelines

2 (0.8)

-

1 (0.3)

1 (0.3)

1 (0.4)

1 (0.3)

2 (0.4)

8 (0.4)

Followed guidelines

13 (0.3)

3 (0.1)

5 (0.1)

14 (0.3)

14 (0.3)

10 (0.2)

8 (0.2)

67 (0.2)

Did not follow guidelines

2 (0.8)

-

1 (0.3)

-

-

-

1 (0.2)

4 (0.2)

Followed guidelines

745 (14.5)

921 (16.2)

897 (19.1)

1077 (22.5)

1333 (26.8)

1409 (29.8)

1417 (30.9)

7799 (22.5)

Did not follow guidelines

55 (22.3)

27 (12.9)

72 (20.7)

70 (19.9)

71 (28.0)

105 (34.7)

167 (34.4)

567 (25.8)

Followed guidelines

14 (0.3)

33 (0.6)

111 (2.4)

124 (2.6)

178 (3.6)

210 (4.4)

210 (4.6)

880 (2.5)

Did not follow guidelines

1 (0.4)

-

14 (4.0)

9 (2.6)

12 (4.7)

9 (3.0)

23 (4.7)

68 (3.10)

Followed guidelines

640 (12.4)

769 (13.5)

802 (17.0)

882 (18.4)

964 (19.3)

932 (19.7)

888 (19.4)

5877 (17.0)

Did not follow guidelines

50 (20.2)

21 (10.1)

74 (21.3)

69 (20.5)

59 (23.2)

62 (20.5)

87 (17.9)

422 (19.2)

Penicillin-resistance
Followed guidelines
Did not follow guidelines
Tetracycline-resistance
Followed guidelines
Did not follow guidelines
Cefixime- Elevated MIC

Ceftriaxone- Elevated MIC

Ciprofloxacin-resistance

Azithromycin- Elevated MIC

Multidrug Resistance

Note. Column %. Number of observations = 36822, Number of Missing = 335. Followed guidelines n=34625, Did not follow guidelines n=2197. Penicillin-resistance:
MIC ≥ 2.0, Tetracycline-resistance: MIC ≥ 2.0, Cefixime-elevated MIC: MIC ≥ 0.25, Ceftriaxone-elevated MIC: MIC ≥ 0.125, Ciprofloxacin-resistance: MIC ≥ 1.0,
Azithromycin-elevated MIC: MIC ≥ 2.0, Multidrug Resistance = 1 when resistant to more than one antimicrobial.

67
Bivariate analysis of risk factors. The bivariate analysis conducted for research question
2 consisted of measuring the association of each risk factor (race, age, region, sexual orientation,
history of gonorrhea, symptoms, sex for drugs/money, antibiotic use, injection drug use, and
non-injection drug use) with the outcome variable (adherence to CDC STD treatment
guidelines). The chi-square calculations were generated using SAS ‘proc freq’ procedure and the
p-value was used to determine which variables would go into the logistic regression model. The
results from the bivariate analysis uncovered a statistically significant association for all risk
factors with the exception of history of gonorrhea (see Table 6). The total number of
observations for each risk factor varied due to missing data from the various fields. The overall
sample size is 37,157 observations.
Table 6
Survey: Chi-square Results from the Bivariate Analysis of Risk Factors and CDC STD
Treatment Guidelines
Risk Factors
a

N

Degrees of
Freedom
3
8
1
1

X2

p-value

Race
36822
203.13
<0.0001
Age Category
36812
79.64
<0.0001
Sex Orientation
36443
138.65
<0.0001
History of
35600
2.03
0.1544
gonorrhea
Sex for
29156
1
27.18
<0.0001
Drugs/Money
Antibiotic
27853
1
9.06
0.0026
IDU
31503
1
39.65
<0.0001
Non-IDU
30707
1
8.64
0.0033
Region
36822
3
126.14
<0.0001
Note. Number of observations = 37157, total N = 52,578. a Age: 1= 1-19, 2 = 20-24, 3 = 25-29,
4 = 30-34, 5 = 35-39, 6 = 40-44, 7 = 45-49, 8 = 50-54, 9 = 55+. b Race: 1=White, 2=Hispanic,
3=Other, 4=Black. c For all Variables: 1=Yes, 2=No.
b

Bivariate analysis of risk factors: Race. Race was constructed into four groups to
include Black, White, Hispanic, and Others. In evaluating the association of race with the
outcome variable, the total number of observations were N=36822 and was statistically
significant with a p-value of <0.0001 (see Table 7). Due to low cell counts (below 5
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observations) for some of the race categories, race was recategorized into four categories: Black,
White, Hispanic, and other. Of those, 58.8% were Black, 20.5% White, 13.9% Hispanic, and
6.8% were other races (i.e., Asian, Native Hawaiian, American Indian, Multi-race). Blacks were
had the highest percentage of men treated per CDC guidelines as well as those not treated per
guidelines. More Whites, than those of other races, were not treated per CDC STD guidelines.
Blacks and Hispanics had a higher percentage of men that were treated per guidelines.
Table 7
Survey: Race Distribution of Men by Treatment Per CDC STD Guidelines
Race

Treated per CDC
Guidelines

Not Treated per CDC
Guidelines

Total

n (%)

n (%)

N (%)

Black

20564 (59.4)

1084 (49.3)

21648 (58.8)

White

6856 (19.8)

709 (32.3)

7565 (20.5)

Hispanic

4865 (14.1)

249 (11.3)

5114 (13.9)

Other

2340 (6.8)

155 (7.1)

2495 (6.8)

Total
34625 (94.0)
2197 (6.0)
36822 (100)
Note. Percentages are column percentages. Number of observations = 36822,
Number of Missing = 335. X2 = 203.1. Degrees of Freedom = 3. p-value <.0001.

Bivariate analysis of risk factors: Age. Age distribution was assessed using the
constructed age category variable. The cross tabulation of age category with the outcome
variable included a total of n=36,812 observations and was statistically significant with a p-value
of <0.0001. When measuring the association of age with the outcome variable, young adults
between the ages of 20-24 and 25-29 years old had the highest rates of gonorrhea, 25% and 24%
respectively (see Table 8). In comparing those treated per CDC guidelines versus those who
were not, there is not much difference within or across age categories. A majority of the
percentages for treated per guidelines and not treated per guidelines within an age category were
very close with only a <1% difference. Men that were 35-39 and older than 55 years old showed
approximately a 2% higher percentage for not being treated per CDC guidelines. Young adult
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men between the ages of 20-24 yeas old were treated per CDC guidelines at a rate 4% higher
than those that were not.

Table 8
Survey: Age Distribution by Adherence to CDC STD Treatment Guidelines
Age (Years)

1-19
20-24

Treated Per CDC
Guidelines
n (%)
2675 (7.7)
8867 (25.6)

Not Treated Per CDC
Guidelines
n (%)
103 (4.7)
470 (21.4)

Total
N (%)
2778 (7.6)
9337 (25.4)

25-29
30-34
35-39
40-44
45-49
50-54
≥ 55

8149 (23.5)
5244 (15.2)
3172 (9.2)
2223 (6.4)
1696 (4.9)
1288 (3.7)
1302 (3.8)

532 (24.2)
352 (16.0)
244 (11.1)
144 (6.6)
136 (6.2)
87 (4.0)
128 (5.8)

8681 (23.6)
5596 (15.2)
3416 (9.3)
2367 (6.4)
1832 (5.0)
1375 (3.7)
1430 (3.9)

Total

34616 (94.0)

2196 (6.0)

36812 (100)

Note. Percentages are column percentages. Number of observations = 36812, Number of
Missing = 345. X2 = 79.64. Degrees of Freedom = 8. p-value <.0001. Mean = 30.8. Median
= 28. Min = 2. Max = 84.

Bivariate analysis of risk factors: Sexual orientation. The sexual orientation of men
in this study was assessed by categorizing men as ‘Men who have sex with men’ (MSM) or
‘Men who have sex with women only’ (MSW). The cross tabulation of sex orientation included
a total of n=35,600 observations and was not statistically significant for a 95% confidence level
with a p-value of 0.1544. The majority of the men in this sample (63%) were classified as MSW
(heterosexual, see Table 9). Of those that were treated per CDC guidelines (n=34,283), 64%
were MSW and 36% were MSM. When observing the sexual orientation of those that were not
treated per CDC STD guidelines, there isn’t much of a difference between the two groups with
49% MSM and 51% MSW. A larger percentage of MSM in comparison to MSW were not
treated per guidelines with MSM at 7.8% and MSW at 4.8%.
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Table 9
Survey: Comparison of Sexual Orientation by Adherence to CDC STD Treatment Guidelines
Sexual Orientation

Treated Per CDC
Guidelines
n (%)

Not Treated Per
CDC Guidelines
n (%)

Total
N (%)

Men who have sex
with men (MSM)

12303 (35.9)

1047 (48.5)

13350 (36.6)

Men who have sex
with women only
(MSW)

21980 (64.1)

1113 (51.5)

23093 (63.4)

Total

34283 (94.1)

2160 (5.9)

36443 (100)

Note. Percentages are column percentages. Number of observations = 36443, Number of
Missing = 714. X2 = 138.65. Degrees of Freedom = 1. p-value <.0001.

Bivariate analysis of risk Factors: History of gonorrhea. The bivariate analysis of
the history of gonorrhea included a total of 36,443 observations and was statistically significant
with a p-value of <0.0001. Men were asked about their history of gonorrhea in the previous 12
months and 52% reported having had gonorrhea (see Table 10). Of those not treated per CDC
guidelines, 53% had a history of gonorrhea and 47% did not. In observing differences in
percentages across the given categories, there doesn’t seem to be much variation with those
with a history of gonorrhea making up about 52% of each category for the dependent variable
and those without a history of gonorrhea making up approximately 48% for each. Likewise,
both those with a history of gonorrhea and those with no history had 6% of men that were not
treated per CDC guidelines.
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Table 10
Survey: Previous Confirmed Episodes of Gonorrhea in the Previous 12 Months by Adherence to
CDC STD Treatment Guidelines
History of
Gonorrhea

Treated Per CDC
Guidelines
n (%)

Not Treated Per
CDC Guidelines
n (%)

Total
N (%)

Men who have history
of gonorrhea

17299 (51.6)

1103 (53.2)

18402 (51.7)

Men who have no
history of gonorrhea

16228 (48.4)

970 (46.8)

17198 (48.3)

Total

33527 (94.2)

2160 (5.9)

35600 (100)

Note. Percentages are column percentages. Number of observations = 35600, Number of
Missing = 1557. X2 = 2.03. Degrees of Freedom = 1. p-value = 0.1544.

Bivariate analysis of risk factors: Sex for drugs/money in previous 12 months. The
bivariate analysis for men who have a history of receiving sex for money or drugs included
n=29,156 observations and was statistically significant with a p-value of <0.0001. A majority of
the men in the study (96%) reported having no history of receiving sex for money or drugs (see
Table 11). Of the 951 men that reported having sex for money or drugs, 8% were not treated per
CDC guidelines compared to 4% not treated per guidelines among men with no history of
having sex for money/drugs.
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Table 11
Survey: Sex in Exchange for Money or Drugs in the Previous 12 Months by Adherence to CDC
STD Treatment Guidelines
Sex for Money/Drugs

Treated Per CDC
Guidelines
n (%)

Not Treated Per
CDC Guidelines
n (%)

Total
N (%)

Men who have a history
of receiving sex for
money or drugs

874 (3.1)

77 (5.7)

951 (3.3)

Men who have no
history of receiving sex
for money or drugs

26938 (96.9)

1267 (94.3)

28205 (96.7)

Total

27812 (95.4)

1344 (4.6)

29156 (100)

Note. Percentages are column percentages. Number of observations = 29156, Number of
Missing = 8001. X2 = 27.18. Degrees of Freedom = 1. p-value <.0001.

Bivariate analysis of risk factors: Antibiotic use in previous 12 months. A bivariate
analysis of the association between antibiotic use in the previous 12 months and adherence to
CDC STD treatment guidelines included 27,853 records with a statistically significant p-value
of 0.0026. Overall, 96% of the men in the study received treatment per CDC guidelines (see
Table 12). Antibiotic use was reported by 11% of the men in the study and 89% stated that they
had no previous use of antibiotics in the last 12 months. Five percent of the men who used
antibiotics during the previous 12 months and 4% of the men that did not use antibiotics were
not treated per CDC STD treatment guidelines.
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Table 12
Survey: Antibiotic Use During the Previous 12 Months by Adherence to CDC STD Treatment
Guidelines
Sex for
Money/Drugs
Men who used
antibiotics during
previous 12 months
Men with no
antibiotic use
during previous 12
months
Total

Treated Per CDC
Guidelines
n (%)

Not Treated Per
CDC Guidelines
n (%)

Total
N (%)

2870 (10.8)

166 (13.5)

3036 (10.9)

23755 (89.2)

1062 (86.5)

24817 (89.1)

26625 (95.6)

1228 (4.4)

27853 (100)

Note. Percentages are column percentages. Number of observations = 27853, Number of
Missing = 9304. X2 = 9.06. Degrees of Freedom = 1. p-value = 0.0026.

Bivariate analysis of risk factors: injection drug use in previous 12 months. In
evaluating the relationship between injection drug use and adherence to CDC STD treatment
guidelines, the bivariate analysis included 31,503 observations and was statistically significant
with a p-value of <0.0001. A very small portion of men reported injection drug use with 721 out
of 31,503 having IDU in the past 12 months, making up only 2% of the sample (see Table 13).
Of the men with a history of IDU in previous 12 months, 9% were not treated per CDC
guidelines. Only 4% of men who reported no IDU were not treated per CDC guidelines.
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Table 13
Survey: History of Injection Drug Use from Previous 12 Months by Adherence to CDC STD
Treatment Guidelines
History of Injection
Drug Use (IDU)

Treated Per CDC
Guidelines
n (%)

Not Treated Per
CDC Guidelines
n (%)

Total
N (%)

Men with a history of
IDU in previous 12
months

654 (2.2)

67 (4.7)

721 (2.3)

Men with no history of
IDU in previous 12
months

29434 (97.8)

1348 (95.3)

30782 (97.7)

Total

10088 (95.5)

1415 (4.5)

31503 (100)

Note. Percentages are column percentages. Number of observations = 31503, Number of
Missing = 5654. X2 = 39.65. Degrees of Freedom = 1. p-value <.0001.

Bivariate analysis of risk factors: Non-injection recreational drug use in previous
12 months. Non-injection recreational drug use had very different results than IDUs. There was
a total of 30,707 observations used to conduct the bivariate analysis and was statistically
significant with a p-value of 0.0033. Twenty-nine percent of men in this study reported having a
history of non-injection drug use in the previous 12 months (see Table 14). Among the men that
were not treated per CDC guidelines, 32% had history of non-IDU and 68% did not have any
history of non-IDU. There were 443 out of 8,817 (5%) men with a history of non-IDU who were
not treated per CDC guidelines. In contrast, there were 932 out of 21,890 (4%) men with no
history of non-IDU that did not receive treatment as recommended by CDC STD guidelines.
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Table 14
Survey: History of Non-injection Recreational Drug Use from Previous 12 Months by Adherence
to CDC STD Treatment Guidelines
History of Noninjection Drug Use
(Non-IDU)

Treated Per CDC
Guidelines
n (%)

Not Treated Per
CDC Guidelines
n (%)

Total
N (%)

Men with a history of
Non-IDU in previous
12 months

8374 (28.6)

443 (32.2)

8817 (28.7)

Men with no history of
Non-IDU in previous
12 months

20958 (71.4)

932 (67.8)

21890 (71.3)

Total

29332 (95.5)

1415 (4.5)

30707 (100)

Note. Percentages are column percentages. Number of observations = 30707, Number of
Missing = 6450. X2 = 8.64. Degrees of Freedom = 1. p-value = 0.0033.

Bivariate analysis of region. The four region categories constructed by using the
reporting jurisdictions were analyzed to identify the association with the dependent variable. The
bivariate analysis was conducted for 36,822 records with a statistically significant p-value of
<0.0001. Overall, the highest number of gonorrhea cases were from the West region followed by
the Midwest and South with the lowest number in the Northeast region. Among the 29,332 men
that were treated per CDC guidelines, 37% were from the West, 27% from the Midwest, 24%
from the South, and 11% from the Northeast (see Table 15). Men who were not treated per CDC
guidelines were primarily from the West (49%) with 21% from the Midwest and South and 9%
from the Northeast. Of men who were treated per CDC guidelines, 37% were from the West
region, 27% from the Midwest, 24% from the South, and 11% from the Northeast.
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Table 15
Survey: Comparison of Gonorrhea Cases across Regions by Adherence to CDC STD Treatment
Guidelines
Region

Treated Per CDC
Guidelines
n (%)

Not Treated Per
CDC Guidelines
n (%)

Total
N (%)

Midwest

9329 (26.9)

459 (20.9)

9788 (26.6)

Northeast

3888 (11.2)

189 (8.6)

4077 (11.1)

South

8446 (24.4)

466 (21.2)

8912 (24.2)

West

12962 (37.4)

1083 (49.3)

14045 (38.1)

Total

29332 (95.5)

1415 (4.5)

36822 (100)

Note. Percentages are column percentages. Number of observations = 36822,
Number of Missing = 335. X2 = 126.14. Degrees of Freedom = 3. p-value <.0001.
Logistic Regression Models
A binomial logistic regression was conducted to determine the effects of age, race,
region, sexual orientation, having sex for drugs/money, antibiotic use, injection drug use, and
non-injection recreational drug use on the likelihood that participants that received treatment per
CDC STD treatment guidelines. The logistic regression model was statistically significant with a
chi-square estimate of 𝜒2 = 3.60, p-value = <.0001 (see Table 16). Of the eight independent
variables, five were statistically significant: age, race, region, sexual orientation, and having sex
for drugs/money. Men between the ages of 20-24 years old were 48% times less likely to have
received treatment per CDC guidelines than those 55 years old and older. Whites were 24% less
likely than Blacks to have received treatment per CDC guidelines. The odds of receiving
treatment according to CDC STD guidelines is 21.5% less likely in men in the Midwest than for
men in the West region. The likelihood that men in the South will receive treatment per CDC
guidelines is 42% less likely than men in the West. Men who have sex with men are 26.8% times
less likely to received treatment per CDC guidelines than men who have sex with women only.
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The likelihood that men who had sex for drugs or money received treatment per CDC guidelines
is 42.9% less than those that had never had sex for drugs or money in the previous 12 months.
Table 16
Moderator Analysis: Logistic Regression Model for Measuring Associations of Demographic
Risk Factors with Adherence to CDC Treatment Guidelines
Effect

Adjusted
Odds Ratio

Fixed effects
Intercept
Age A

SE

95% CI
LL

UL

P-value

3.963
.986

.129
.003

.980

.991

<.0001*
<.0001

.760

.089

.639

.905

.002*

Hispanic

1.174

.117

.934

1.476

.170

Others

1.113

.160

.814

1.522

.504

.782

.086

.661

.926

.004*

1.185

.212

.783

1.793

.423

South vs west
Sexual orientation (MSM VS MSW)D

.577
.731

.095
.073

.479
.634

.695
.843

<.0001*
<.0001*

Sex for drugs/money in previous 12
months D
Antibiotic use in previous 12 months D

.568

.149

.424

.760

.0001*

.922

.111

.742

1.146

.464

Injection drug use in previous 12
months D
Non-injection recreational drug use in
previous 12 months D

.793

.197

.539

1.167

.240

.900

.072

.782

1.036

.144

Race (vs black)
White

Region (vs west)
Midwest vs west
Northeast vs west

Note. Number of observations used = 24,067 number of effects = 782, total N = 37,157. CI =
confidence interval; LL = lower limit; UL = upper limit.
a
Age: contiunous variable. c Study year was grand centered. d For all Variables: 1=Yes, 2=No.

Chapter Summary
The 2012-2018 GISP data were analyzed and assessed to measure associations between
independent and dependent variables by conducting bivariate and logistic regression analyses.
Each research question was addressed, and the outcome of the analyses were outlined in this
chapter.
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Question 1: What trends in antimicrobial susceptibility patterns exist in strains of N.
gonorrhoeae among men who received the recommended treatment per STD Treatment
Guidelines versus those who received alternative regimens?
Hypothesis 1A: Men who received alternative treatment regimens for N. gonorrhoeae are more
likely to have resistance to multiple drugs than those treated per treatment guidelines. Evidence
in this study supports this hypothesis.
In evaluating the relationship between antimicrobial susceptibility patterns and the
dependent variable of participants who received treatment per STD Treatment Guidelines versus
those who received alternate regimens, a bivariate analysis was conducted. Ciprofloxacin and
Multidrug resistance were the only two drug patterns that were statistically significant at a 95%
confidence level with p-values of 0.0004 and <.0001, respectively. The trend of Ciprofloxacin
resistance between 2012 and 2018 was highest across all years, with the exception of 2013 and
2015, among men who received alternate regimens for treatment. Multidrug resistance resulted
in the exact same trend as ciprofloxacin with men receiving alternate treatment regimen having
higher resistance for all years minus 2013 and 2015. Therefore, based on the results presented
for Research Question 1, the hypothesis that men who received alternative treatment regimens
are more likely to have multiple drug resistance is confirmed.
Question 2: What risk factors are associated with having received treatment per STD Treatment
Guidelines versus not?
A bivariate analysis was first conducted to measure the significance of the relationships
of the outcome variable with the risk factor variables: race, age, region, sexual orientation,
history of gonorrhea in past year, sex for money/drugs, history of antibiotic use in last 12
months, history of injection drug use in last 12 months, and history of non-injection recreational
drug use in last 12 months. Independent variables that were statistically significant were then
included in the logistic regression model. All risk factors, with the exception of history of
gonorrhea in the last 12 months, were statistically significant with a p-value less than 0.05 and
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were included in the model. After accounting for potential confounding, the variables that had a
statistically significant association were age (20-24 and 35-39 years), race (white vs black),
region (Midwest and South vs West), sexual orientation, and sex for drugs/money.
•

Hypothesis 1B: Black men are more likely to have not received the recommended treatment
compared to men in other race categories. Evidence in this study does not support this
hypothesis.

•

Hypothesis 2B: Men between the ages of 15-24 are more likely to receive alternative
regimens than other age categories. Evidence in this study supports this hypothesis.

•

Hypothesis 3B: Men who have sex with men are more likely to have received an alternate
method of treatment compared to men who have sex with women only. Evidence in this
study supports this hypothesis.

•

Hypothesis 4B: Men with previous confirmed episodes of gonorrhea in the past year are
more likely to have received the recommended treatment regimen than men with no prior
episodes. Evidence in this study does not support this hypothesis. No difference between
the two groups were identified.

•

Hypothesis 5B: Men who have a history in the previous 12 months of risky sexual behavior
or drug use are less likely to have received the recommended treatment. Evidence in this
study supports this hypothesis.

•

Hypothesis 6B: Men in the South are more than likely to be treated with alternative
regimens than those in other regions. Evidence in this study does not support this
hypothesis.
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CHAPTER 5
DISCUSSION
This chapter provides an interpretation of the results of this study relative to previous
research published on this topic. In addition, the implications for public health practice, limitations,
and suggestions for future research are presented. The purpose of this study was to identify risk
factors that are associated with and trends in antimicrobial susceptibility patterns that exist in strains
of N. gonorrhoeae identified through GISP participants who received treatment as recommended by
CDC STD Treatment guidelines versus those that received alternative regimens. The risk factors
associated with gonococcal infections may not be the same risk factors associated with developing
AMR-NG; therefore, it is extremely important that we characterize factors associated with AMR-NG
to assist with controlling the growing public health concern and informing policies around the use of
antimicrobials. The 2015 CDC-recommended treatment therapy for gonorrhea was ceftriaxone (a
cephalosporin antimicrobial) combined with azithromycin. There is a major concern for the spread of
the extended-spectrum cephalosporin (ESC)-resistant N. gonorrhoeae, given that the emergence of
this resistance strand will severely limit treatment options for gonorrhea in the U.S. and globally
(Unemo et al., 2019). Understanding this risk factors also helps target interventions to populations
with a higher risk of AMR-NG infection (Trecker et al., 2014).The socio-ecological model was used
as a reference framework to align the research and findings of this study with the five levels of
interaction that may influence the attitudes and behaviors of participants.
In assessing the association of risk factors with the treatment for gonorrhea per CDC STD
guidelines versus an alternative regimen, we observed interactions at the individual, interpersonal,
organizational, and community levels of the socio-ecological model (see Figure 11). The individual
characteristics that influence the behavior of participants in this study are race, age, sexual
orientation, history of gonorrhea, and antibiotic use in the previous 12 months. Interpersonal
characteristics that were assessed were whether the participant had sex for money or drugs in the
previous 12 months, and if there was a history of injection or non-injection recreational drug use in
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the previous 12 months. Antimicrobial treatment per CDC STD Treatment Guidelines provided
influence at the organizational level, and the influence of a participant’s region of residence was
evaluated at the community level.
Figure 11
Summary of Results by Each Level of the Socio-Ecological Model

Individual Level
Race/ethnicity. Research demonstrates that some racial or ethnic minority groups have a
higher rate of STDs in comparison to their white counterparts (CDC, 2019a). In evaluating race
disparities associated with gonorrhea treatment in this study, race was recategorized as White, Black,
Hispanic, and other. Although the prevalence of gonorrhea in Blacks was 7.7 times higher than in
Whites in 2018, Whites were less likely to have received treatment per CDC STD treatment
guidelines than Blacks. Overall, the percentage of participants that did not receive treatment per
guidelines were low, however, 9% of Whites did not receive treatment per guidelines compared to
only 5% in Blacks.
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Age. In assessing disparities across age categories, adolescents and young adults are more
susceptible to STD infections because of behavioral, biological, and cultural reasons. There are
approximately 19 million new cases of STDs that occur annually in the U.S., and of those, people
between the ages of 15 and 24 years make up of about 50% of all cases (CDC, 2019a). Similar to
previous findings, young adults between the ages of 20-24 and 24-29 years old make up 25% and
24% (for a total of 50%) of gonorrhea cases in this study, respectively. However, when observing
whether age played a role in what treatment was provided, there were no significant differences
across the age categories. Stefanelli and colleagues (2017) also found that there were no significant
results at the multivariate analysis when observing differences in age groups. In Europe, resistance
isolates of gonorrhea here more frequent from those older than 25 years old versus their younger
counterparts which is similar to our findings in this study.

Sexual orientation. In contrast to women and men who only have sex with women, men
who have sex with men (i.e., gay, bisexual, and other MSMs) have a higher incidence of STDs
(CDC, 2019a). Due to delayed treatment, or a lack thereof, MSM display a higher rate of
antimicrobial resistance to Azithromycin and Ceftriaxone in comparison to MSW, as shown in
Figure 2-4 (CDC, 2019a). Unemo and colleagues (2019) noted that data from GISP was pivotal in
alerting public health officials about the increasing prevalence of gonorrhea among MSM in the late
1990’s. In 2004, GISP data were also used to recommend that fluoroquinolones not be used among
MSM with gonorrhea (Unemo et al., 2019). The population of men with gonorrhea in this study was
primarily MSW, making up 63% of the sample, and the remaining 37% were MSM. There was no
statically significant difference in treatment regimen between the two groups, however, of those that
were treated per CDC treatment guidelines, 64% were MSW and 36% were MSM. Among men that
received an alternative treatment regimen, the two groups were approximately evenly distributed.
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Previous history of gonorrhea. A Euro-GASP analysis reported that having had gonorrhea
in the past will increase the risk of being infected by resistant isolates (Cole, 2014). Stefanelli and
colleagues (2017) found that patients with a previous history of gonorrhea were 1.81 times more
likely of being infected by resistant isolates than those with no history. The Stefanelli (2017) study
also found that patients with a previous history of gonorrhea were 3.58 times more likely to have
received treatment discordant with the guidelines compared to those with no previous diagnosis. In
our study, we found no differences in treatment between those with a previous history of gonorrhea
and those with no previous diagnosis. Both groups had 6% of patients that were not treated per
guidelines.

Previous history of antibiotic use. Since 1997, there has been an increase in incidence of
gonorrhea that can be attributed to the growing numbers of treatment failure as a result of untreatable
multidrug resistant gonorrhea strains (CDC, 2019a). In previous studies, there was a direct
correlation with the implementation of combined therapy in clinical settings and a decline in
resistance to azithromycin and cefixime (Stefanelli et al., 2017). In contrast to previous studies, we
also assessed the association of the use of antimicrobials in the previous 12 months. In doing so, we
found that antibiotic use was reported by 11% of the men in the study and 89% stated that they had
no previous use of antibiotics in the last 12 months. Five percent of the men who used antibiotics
during the previous 12 months and 4% of the men that did not use antibiotics were not treated per
CDC STD treatment guidelines.

Interpersonal
Sex for money/drugs and drug use (IDUs and Non-IDUs). Many studies have shown that
commercial sex exchanges for money, drugs, etc. have a direct impact on the progression of the HIV
and STD epidemics. Previous studies have found that male sex workers are three times more likely
to have injection drug or cocaine use in the past four months (Wagner et al., 2013). In this study,
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however, only 951 (3.3%) of the 29,156 respondents to the question reported having had sex for
money or drugs in the previous 12 months. Of the 951 men that reported having sex for money or
drugs, 8% were not treated per treatment guidelines compared to 4% among men with no history of
having sex for money/drugs. There is very little research available that examines the overlap between
the sexual partner types for male/female sex workers and drug use within a given population.

Organizational
Antimicrobial treatment per CDC guidelines. The history of altering recommendations
for gonorrhea treatment have been influenced by surveillance and diagnostic testing methods (Hook
& Kirkcaldy, 2018). Therefore, gaining an understanding of how these influences, along with other
risk factors, impact current treatment approaches will assist in addressing the re-emerging challenge
of AMR-NG. In conducting a trend analysis of antimicrobial susceptibility in NG isolated in Italy,
Stefanelli and colleagues (2017) found that gonorrhea isolates showed a shift in antimicrobial
susceptibility following implementation of the revised recommendations for gonorrhea treatment
(combined therapy with CRO plus AZM). Prior to these changes, gonorrhea in Italy showed high
levels of resistance to AZM 2007-2008 and CFM in 2009 (Stefanelli et al., 2017). In this study, there
was only a statistically significant association between CIP-R and MDR-NG. When reviewing the
antimicrobial susceptibility trends among men who received treatment for gonorrhea per CDC
guidelines versus those who did not, we see an increase in resistance to ciprofloxacin after 2015
among men who were not treated per CDC guidelines. Prior to 2015 the difference between the two
outcome groups varied. However, ciprofloxacin resistance in men not receiving treatment per CDC
guidelines was higher overall with the exception of years 2013 and 2015.

Community
Region. When changes to CDC’s STD treatment guidelines are made, State and local health
departments receive notification via dear colleague letters, Morbidity and Mortality Weekly Report
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article, and other forms of media outlets to ensure national implementation of changes. Previous
studies have shown revisions to national guidelines often lead to a decrease in the use of
antimicrobials that are no longer recommended for treatment (Dowell et al., 2012). Particularly,
Dowell and colleagues (2012) found that all fluoroquinolone use decreased more than 20% after
publication and dissemination of revised national guidelines that removed fluoroquinolones from
recommended treatments for gonorrhea. In assessing fluoroquinolone prescribing practices by
geographic area and practice setting, they also found that fluoroquinolone prescribing decreased
significantly and more abruptly in STD clinics compared to a gradual change in primary care and in
emergency department, urgent care, and hospital settings. Fluoroquinolone prescribing decreased
significantly and by large magnitudes in Denver and Richmond, decreased significantly but by
smaller magnitudes in Hartford and New Haven and in Minneapolis, and decreased non-significantly
in Baltimore (Dowell et al., 2012).
In this study, the highest number of gonorrhea cases were from the West region followed by
the Midwest and South with the lowest number in the Northeast region. Among the 29,332 men that
were treated per CDC guidelines, 37% were from the West, 27% from the Midwest, 24% from the
South, and 11% from the Northeast. Men who were not treated per CDC guidelines were primarily
from the West (49%) with 21% from the Midwest and South and 9% from the Northeast. The odds
of receiving treatment according to CDC STD guidelines is 21.5% less likely in men in the Midwest
than for men in the West region. The likelihood that men in the South will receive treatment per
CDC guidelines is 42% less likely than men in the West.

Combined Interaction
Antimicrobial susceptibility. The trends of antimicrobial susceptibility are influenced by
variables across the four categories of the socio-ecological model that are represented in this study.
Antimicrobial susceptibility is influenced at the individual, interpersonal, organizational, and
community levels. In observing susceptibility patterns across various countries, previous studies
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found that AZM and CFM resistance declined over the years following the implementation of
combined therapy in clinical practice for treatment of gonorrhea (Stefanelli et al., 2017). In assessing
the association between patient characteristics and antimicrobial susceptibility, Stefanelli and
colleagues (2017) found that the odds of having AMR-NG to at least one antimicrobial was 21%
higher in MSWs than in MSMs and isolates from older patients (>25 years) were 14% more likely to
be resistant than younger patients. In the same study, those that were significantly more likely to
receive treatment other than recommended guidelines were MSWs, those with previous history of
gonorrhea, the co-infected, older subjects (>25 years), East Europeans, and pharyngeal or anorectal
infections.

Limitations
The empirical results reported in this study should be considered in light of some limitations.
One potential limitation is that the analysis conducted in this study was restricted to data from me.
The data retrieved from GISP only contains men urethral samples. Women tend to be more likely to
adhere to antimicrobial treatment and tend to have more susceptibility than men, so the inclusion of
data from women is unlikely to impact the results (Kirkcaldy et al., 2017). Women are included in
the eGISP as of 2018, so future assessments may be of interest. A second limitation is the data are
collected before patients are treated and thus are unable to determine how being treated with an
alternative drug impacts their future AMR-GC profile. Another limitation of this dataset is that it
does not account for repeat cases. In the event that a patient has multiple infections within a given
time period, each visit is entered as a unique record. The sites included in GISP are primarily STD
clinics so private practices and those being tested in other outpatient settings are not accounted for in
this sample. This may be of significance because patients visiting STD clinics may differ in
demographics than those in private settings. The final limitation is a lack of research looking at risk
factors and trends in antimicrobial susceptibility following change in STD treatment guidelines.
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Strengths
A major strength of this study is the large dataset that provides power and validity to the
statistical findings. The strengths of the study also include an in-depth assessment of antimicrobial
susceptibility trends over time and across various risk factors. The geographical representation of
the STD clinics that were sampled across approximately 18-25 sentinel sites in the US provide
representation in all regions and allows for generalizability of results.

Implications for Public Health Practice
The principal theoretical implication of this study is that reduced susceptibility and
antimicrobial resistance to gonorrhea is an increased burden influenced by various risk factors, and
the failure to maintain stewardship of antimicrobials can lead to long-term complications. The
epidemiology of antimicrobial resistance guides decisions about gonococcal treatment
recommendations and has evolved because of shifts in antimicrobial resistance patterns (CDC,
2015). As trends in resistance increase, we may be forced to make more frequent changes to STD
guidelines essentially running out of treatment options. As treatment options become limited, there
will also be an inability for practitioners to effectively treat gonorrhea. If gonorrhea becomes
untreatable, we will then see an increase of chronic or more severe illnesses, such as PID, as a result.
Failure to address the health disparities and disproportionate rates of gonorrhea will continue to
progressively impact high risk groups and communities.

Recommendations for Future Research
Further research might explore similar modeling utilizing data that includes gonococcal
isolates from both men and women, as in the CDC eGISP. Additional investigation and
experimentation can be conducted immediately following a change in STD treatment guidelines. A
retrospective cohort study can be implemented to follow participants over time, after administration
of treatment, in order to monitor antimicrobial susceptibility and other risk factors. Another possible
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area of future research would be to conduct special studies in at-risk populations to identify the
attitudes, behaviors, and beliefs of patients and practitioners serving these populations. This
expansion in research will help to identify discrepancies in administration of treatment, time-lapse
between symptom onset or exposure and seeking care, adherence to treatment regimens, and other
risk behaviors associated with antimicrobial resistant gonorrhea. Another future research approach
can possibly include sexual partner(s) interviews and counseling to identify other potential risk
factors and preventive methods within sexual networks. Information on condom use, travel,
coinfection with other STDs, more information on poverty and insurance coverage, income,
employment, and educational level would help us to establish a greater degree of accuracy on the
impact of health disparities on treatment regimens.

Conclusion
Overall, treatment of gonorrhea was prescribed as recommended. The percentages of
ceftriaxone resistance have shown a decrease since 2015, which correlates with the implementation
of the most recent CDC STD treatment guidelines of 2015. Conclusively, information on treatment
regimens before and after implementation of STD treatment guidelines can be useful in assessing
treatment practices and adherence to guidelines in treating gonorrhea particularly in populations at
risk of antimicrobial resistant gonorrhea. A majority of the drug classes that are typically used to
treat gonorrhea have lost their efficacy and now have reduced susceptibility or have acquired
resistance to the bacteria. Strategies for treatment of gonorrhea should be based on the surveillance
of antimicrobial resistance at both the local/regional and national levels and data for treatment
practices and failures should also be considered. Given that the actual global burden of disease is
unknown, it is also critical that global efforts work to improve the quality-assured surveillance of
AMR-NG and that failures in gonorrhea treatment, when using the recommended treatment regime,
are verified both domestically and internationally (Unemo et al., 2019).
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APPENDIX: OPERATIONALIZATION OF VARIABLES FROM THE GONOCOCCAL
ISOLATE SURVEILLANCE PROJECT, 2012-2018

Variable Name
PATIENT

Type of
Variable
Independent

DATEVIS

Independent

YRMO

Independent

YEAR

Independent

RACEALL

Independent

Description
unique identifier
date of clinic
visit
Year/Month of
patient’s visit
4-character year
code
Combination of
race and
ethnicity
variables check all that
apply - mutually
exclusive

BLACKWHITE Independent
(Constructed)

Values
clinic-yrmo-id (4-digit
year)
MM/DD/YYYY

Research
Question
1, 2
1, 2

YYYYMM

1, 2

Ex: 2000, 2001, 2001

1, 2

‘0’=’Asian/Natv Haw’
'1'='Amer Ind'
'2'='Asian'
'3'='Black'
'4'='Natv Haw'
'5'='White'
'6'='Other'
'7'='Hispanic'
'8'='Multi-race'
‘9'='Unknown'
1=White
2=Hispanic
3=Other
4=Black

2

2

ETHNIC

Independent

Hispanic origin

1=Hispanic, 2=nonHispanic, 9=Unknown

2

AGE

Independent

age in years

Continuous

2

AGECAT

Independent
(Constructed)

1 = <20 years
2 = 20-24 years
3 = 25-29 years
4 = 30-34 years
5 = 35-39 years
6 = 40-44 years
7 = 45-49 years
8 = 50-54 years
9 = 55+ years

2

SEXOR

Independent

1= women
(heterosexual)
2= men (homosexual)
3=women and men

2

Sex of sex
partner in past 3
months

96
(bisexual)
9= unknown

SEXPARTNER

Independent
(Constructed)

HISTORY

Independent

SEXWK

Independent

ANTIBIOT

Independent

IDU

Independent

NONIDU

Independent

PEN

Independent

TETRACY

Independent

CFX

Independent

CRO

Independent

Homosexual
and bisexual
men were
grouped
together to
create MSM
previous history
of gonorrhea

1=Men who have sex
with women only
(MSW)
2=Men who have sex
with men (MSM)

2

1=yes, 2=no,
9=unknown

2

history of giving
or receiving
drugs/money for
sex in the
previous 12
months
any antibiotic
use during the
previous 12
months
history of
injection drug
use in previous
12 months
history of
noninjection
recreational
drug use
(excluding
alcohol) in the
previous 12
months
penicillin MIC
(µg/ml)
tetracycline
MIC (µg/ml)
cefixime MIC
(µg/ml)

1=yes, 2=no,
9=unknown

2

1=yes, 2=no,
9=unknown

2

1=yes, 2=no,
9=unknown

2

1=yes, 2=no,
9=unknown

2

0.25; 0.5; 1.0; 2.0; 4.0;
8.0; 16.0; 32.0; 64.0
0.25; 0.5; 1.0; 2.0; 4.0;
8.0; 16.0; 32.0; 64.0
0.015; 0.03; 0.06;
0.125; 0.25; 0.5; 1.0;
2.0
0.008; 0.015; 0.03;
0.06; 0.125; 0.25; 0.5;
1.0; 2.0

1, 2

ceftriaxone MIC
(µg/ml)

1, 2
1, 2

1, 2
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CIPRO

Independent

ciprofloxacin
MIC (µg/ml)

AZI

Independent

azithromycin
MIC (µg/ml)

PEN_SUS

Independent
(Constructed)
Independent
(Constructed)
Independent
(Constructed)
Independent
(Constructed)

CIP_SUS
AZI_SUS

TET_SUS
CFX_SUS
CRO_SUS

TRMT1

0.015; 0.03; 0.06;
0.125; 0.25; 0.5; 1.0;
2.0; 4.0; 8.0; 16.0

1, 2

1, 2

penicillin
susceptibility
tetracycline
susceptibility
cefixime
susceptibility
ceftriaxone
susceptibility

0.03; 0.06; 0.125; 0.25;
0.5; 1.0; 2.0; 4.0; 8.0;
16.0; 32.0; 64.0; 128.0;
256.0
1=Resistant
2=Susceptible
1=Resistant
2=Susceptible
1=Elevated MIC
2=Susceptible
1=Elevated MIC
2=Susceptible

Independent
(Constructed)

ciprofloxacin
susceptibility

1=Resistant
2=Susceptible

1, 2

Independent
(Constructed)
Independent

azithromycin
susceptibility
Primary
treatment for
gonorrhea

1=Elevated MIC
2=Susceptible
00=none
03=spectinomycin
(Trobicin) 2 gm
04=ceftriaxone
(Rocephin) 250 mg
05=ceftriaxone
(Rocephin) 125 mg
06=ciprofloxacin (Cipro)
500 mg
07=cefoxitin (Mefoxin) 2
gm
12=cefixime (Suprax)
400 mg
14=cefpodoxime proxetil
(Vantin) 200 mg
15=ofloxacin (Floxin)
400 mg
17=ceftizoxime (Cefizox)
500 mg
18=cefotaxime (Claforan)
500 mg
21=azithromycin
(Zithromax) 2 gm
22=levofloxacin
(Levaquin) 250 mg
23=cefpodoxime proxetil
(Vantin) 400 mg

1, 2

1, 2
1, 2
1, 2
1, 2

1, 2
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TRMT2

Independent

Second
antibiotic
used as part of
dual therapy
for gonorrhea
(and treatment
of chlamydia)

CLINIC

Independent

Sentinel Site
Code

24=ceftibuten (Cedax)
400 mg
25=cefdinir (Omnicef)
300 mg
26=cefdinir (Omnicef)
600 mg
27= gemifloxacin 320 mg
28= gentamicin 240 mg
(or weight-based dosage)
88=other (please indicate
in Other Treatment 1)
99=unknown
00=none
1, 2
01=ampicillin/amoxicillin
09=doxycycline
(Vibramycin)/tetracycline
10=erythromycin
11=azithromycin
(Zithromax) 1 gm
15=ofloxacin
21=azithromycin
(Zithromax) 2 gm
22=levofloxacin
88=other
99=unknown
ALB = Albuquerque
1, 2
ANC= Anchorage
ATL=Atlanta
BAL= Baltimore
BHM=Birmingham
BOS=Boston
BUF= Buffalo
CAM= Camden
CHI=Chicago
CLE = Cleveland
COL=Columbus
DAL=Dallas
DEN=Denver
FSM =Federated States
of Micronesia
GRB=Greensboro
HON=Honolulu
IND=Indianapolis
JAC= Jackson
KCY=Kansas City
LVG=Las Vegas
LA1/LA2=Los Angeles
MIA=Miami
MIL=Milwaukee
MIN=Minneapolis
NOR=New Orleans

99

MULTIRES

Independent
(Constructed)

REGION

Independent
(Constructed)

TREATGUID

Dependent
(Constructed

Is patient
resistant to
multiple
drugs?
Region in
which the
sentinel site is
located
Did the
antimicrobials
used for
treatment
follow CDC
treatment
guidelines

NYC= New York City
ORA=Orange County
PHI=Philadelphia
PHX=Phoenix
PON=Pontiac
POR=Portland
SDG=San Diego
SEA= Seattle
SFO=San Francisco
TRP=Tripler
WDC= Washington, DC
1=Yes
2=No

NE=Northeast
MW=Midwest
S=South
W=West
1=Yes, 2=No

1, 2

2

1, 2

